JP7377802B2 - 免疫療法を用いてhiv/aidsを処置するための組成物および方法 - Google Patents
免疫療法を用いてhiv/aidsを処置するための組成物および方法 Download PDFInfo
- Publication number
- JP7377802B2 JP7377802B2 JP2020534253A JP2020534253A JP7377802B2 JP 7377802 B2 JP7377802 B2 JP 7377802B2 JP 2020534253 A JP2020534253 A JP 2020534253A JP 2020534253 A JP2020534253 A JP 2020534253A JP 7377802 B2 JP7377802 B2 JP 7377802B2
- Authority
- JP
- Japan
- Prior art keywords
- hiv
- car
- acid sequence
- cells
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000030507 AIDS Diseases 0.000 title claims description 30
- 238000000034 method Methods 0.000 title description 82
- 239000000203 mixture Substances 0.000 title description 17
- 238000009169 immunotherapy Methods 0.000 title description 10
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 714
- 150000007523 nucleic acids Chemical class 0.000 claims description 351
- 239000000427 antigen Substances 0.000 claims description 296
- 108091007433 antigens Proteins 0.000 claims description 296
- 102000036639 antigens Human genes 0.000 claims description 296
- 210000004027 cell Anatomy 0.000 claims description 289
- 230000027455 binding Effects 0.000 claims description 280
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 242
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 229
- 230000036436 anti-hiv Effects 0.000 claims description 224
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 184
- 102000039446 nucleic acids Human genes 0.000 claims description 110
- 108020004707 nucleic acids Proteins 0.000 claims description 110
- 239000013598 vector Substances 0.000 claims description 76
- 108090000623 proteins and genes Proteins 0.000 claims description 68
- 230000011664 signaling Effects 0.000 claims description 53
- 241000282414 Homo sapiens Species 0.000 claims description 47
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 40
- 230000004068 intracellular signaling Effects 0.000 claims description 39
- -1 CD137 Proteins 0.000 claims description 38
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 37
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 37
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 37
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 37
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 36
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 36
- 101710091045 Envelope protein Proteins 0.000 claims description 36
- 101710188315 Protein X Proteins 0.000 claims description 36
- 230000003834 intracellular effect Effects 0.000 claims description 35
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- 125000006850 spacer group Chemical group 0.000 claims description 29
- 108091008874 T cell receptors Proteins 0.000 claims description 27
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 27
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 24
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 24
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 18
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 18
- 230000000139 costimulatory effect Effects 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 11
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 9
- 108020004414 DNA Proteins 0.000 claims description 9
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 9
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims description 9
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 8
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 8
- 102100037904 CD9 antigen Human genes 0.000 claims description 7
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 7
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 7
- 102100032937 CD40 ligand Human genes 0.000 claims description 6
- 208000020825 HIV-associated cancer Diseases 0.000 claims description 6
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 6
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 claims description 6
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims description 6
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 6
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 6
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 6
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 6
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 6
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 6
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 6
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 6
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 5
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 5
- 102100027207 CD27 antigen Human genes 0.000 claims description 4
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 4
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 4
- 102100025221 CD70 antigen Human genes 0.000 claims description 3
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 3
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 3
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 3
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 3
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 3
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 3
- 241000712079 Measles morbillivirus Species 0.000 claims description 3
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims description 3
- 230000001177 retroviral effect Effects 0.000 claims description 3
- 241001529453 unidentified herpesvirus Species 0.000 claims description 3
- 239000013601 cosmid vector Substances 0.000 claims description 2
- 239000013600 plasmid vector Substances 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 description 331
- 239000012634 fragment Substances 0.000 description 84
- 235000001014 amino acid Nutrition 0.000 description 73
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 65
- 208000031886 HIV Infections Diseases 0.000 description 64
- 241000700605 Viruses Species 0.000 description 63
- 125000003729 nucleotide group Chemical group 0.000 description 61
- 239000002773 nucleotide Substances 0.000 description 57
- 239000011230 binding agent Substances 0.000 description 56
- 108090000765 processed proteins & peptides Proteins 0.000 description 55
- 241000124008 Mammalia Species 0.000 description 46
- 238000000338 in vitro Methods 0.000 description 42
- 239000012636 effector Substances 0.000 description 39
- 102100034349 Integrase Human genes 0.000 description 38
- 206010028980 Neoplasm Diseases 0.000 description 37
- 108010076504 Protein Sorting Signals Proteins 0.000 description 37
- 230000002147 killing effect Effects 0.000 description 34
- 239000013604 expression vector Substances 0.000 description 33
- 230000006870 function Effects 0.000 description 33
- 230000014509 gene expression Effects 0.000 description 33
- 208000015181 infectious disease Diseases 0.000 description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 32
- 102000004196 processed proteins & peptides Human genes 0.000 description 32
- 230000000694 effects Effects 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 30
- 238000003259 recombinant expression Methods 0.000 description 29
- 201000010099 disease Diseases 0.000 description 25
- 238000003501 co-culture Methods 0.000 description 23
- 238000001727 in vivo Methods 0.000 description 23
- 239000003795 chemical substances by application Substances 0.000 description 22
- 238000011282 treatment Methods 0.000 description 22
- 208000037357 HIV infectious disease Diseases 0.000 description 21
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 21
- 229920001184 polypeptide Polymers 0.000 description 21
- 239000000562 conjugate Substances 0.000 description 20
- 108700004025 env Genes Proteins 0.000 description 20
- 101150030339 env gene Proteins 0.000 description 20
- 230000003612 virological effect Effects 0.000 description 20
- 201000011510 cancer Diseases 0.000 description 19
- 239000003550 marker Substances 0.000 description 19
- 238000006467 substitution reaction Methods 0.000 description 19
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 18
- 108060001084 Luciferase Proteins 0.000 description 16
- 239000005089 Luciferase Substances 0.000 description 16
- 239000003112 inhibitor Substances 0.000 description 16
- 230000001086 cytosolic effect Effects 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 238000011225 antiretroviral therapy Methods 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 230000002458 infectious effect Effects 0.000 description 14
- 102000040430 polynucleotide Human genes 0.000 description 14
- 108091033319 polynucleotide Proteins 0.000 description 14
- 239000002157 polynucleotide Substances 0.000 description 14
- 102000004127 Cytokines Human genes 0.000 description 13
- 108090000695 Cytokines Proteins 0.000 description 13
- 108010052090 Renilla Luciferases Proteins 0.000 description 13
- 230000003013 cytotoxicity Effects 0.000 description 13
- 231100000135 cytotoxicity Toxicity 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 13
- 108010074328 Interferon-gamma Proteins 0.000 description 12
- 239000003053 toxin Substances 0.000 description 12
- 231100000765 toxin Toxicity 0.000 description 12
- 108700012359 toxins Proteins 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 108060003951 Immunoglobulin Proteins 0.000 description 11
- 102100037850 Interferon gamma Human genes 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 102000018358 immunoglobulin Human genes 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 241000701022 Cytomegalovirus Species 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 230000001684 chronic effect Effects 0.000 description 10
- 230000003389 potentiating effect Effects 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- 230000014616 translation Effects 0.000 description 10
- 108010041397 CD4 Antigens Proteins 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000013461 design Methods 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 241000711549 Hepacivirus C Species 0.000 description 8
- 101000801227 Homo sapiens Tumor necrosis factor receptor superfamily member 19 Proteins 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 102100033760 Tumor necrosis factor receptor superfamily member 19 Human genes 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 7
- 102000014914 Carrier Proteins Human genes 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 7
- 102000003886 Glycoproteins Human genes 0.000 description 7
- 108090000288 Glycoproteins Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 108091008324 binding proteins Proteins 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 210000004986 primary T-cell Anatomy 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102100035793 CD83 antigen Human genes 0.000 description 6
- 241000700721 Hepatitis B virus Species 0.000 description 6
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 6
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 6
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000002285 radioactive effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- QWPXBEHQFHACTK-KZVYIGENSA-N (10e,12e)-86-chloro-12,14,4-trihydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-15,16-dihydro-14h-7-aza-1(6,4)-oxazina-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-6-one Chemical compound CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-KZVYIGENSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 102000003735 Mesothelin Human genes 0.000 description 5
- 108090000015 Mesothelin Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 230000000735 allogeneic effect Effects 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000002688 persistence Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 4
- 108010039491 Ricin Proteins 0.000 description 4
- 108010017507 Ricinus communis agglutinin-1 Proteins 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 230000006044 T cell activation Effects 0.000 description 4
- 102000006601 Thymidine Kinase Human genes 0.000 description 4
- 108020004440 Thymidine kinase Proteins 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000005714 functional activity Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- 238000012737 microarray-based gene expression Methods 0.000 description 4
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 108020001580 protein domains Proteins 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 3
- 108010066676 Abrin Proteins 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 102000006306 Antigen Receptors Human genes 0.000 description 3
- 108010083359 Antigen Receptors Proteins 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 108010075254 C-Peptide Proteins 0.000 description 3
- 108091033409 CRISPR Proteins 0.000 description 3
- 206010010144 Completed suicide Diseases 0.000 description 3
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 description 3
- 102000000311 Cytosine Deaminase Human genes 0.000 description 3
- 108010080611 Cytosine Deaminase Proteins 0.000 description 3
- 108010053187 Diphtheria Toxin Proteins 0.000 description 3
- 102000016607 Diphtheria Toxin Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000004961 Furin Human genes 0.000 description 3
- 108090001126 Furin Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 3
- 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 208000032420 Latent Infection Diseases 0.000 description 3
- 108091054438 MHC class II family Proteins 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- QWPXBEHQFHACTK-UHFFFAOYSA-N Maytansinol Natural products CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-UHFFFAOYSA-N 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 102000015636 Oligopeptides Human genes 0.000 description 3
- 108010038807 Oligopeptides Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 206010038705 Respiratory moniliasis Diseases 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 229930195731 calicheamicin Natural products 0.000 description 3
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 230000001461 cytolytic effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 230000002637 immunotoxin Effects 0.000 description 3
- 229940051026 immunotoxin Drugs 0.000 description 3
- 239000002596 immunotoxin Substances 0.000 description 3
- 231100000608 immunotoxin Toxicity 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 230000010415 tropism Effects 0.000 description 3
- 238000007492 two-way ANOVA Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 108700026220 vif Genes Proteins 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 description 2
- GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 description 2
- RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 2
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102100032558 Glypican-2 Human genes 0.000 description 2
- 102100032530 Glypican-3 Human genes 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 2
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 2
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 101001014664 Homo sapiens Glypican-2 Proteins 0.000 description 2
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 description 2
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 description 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 2
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 2
- 101710125507 Integrase/recombinase Proteins 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 241000186363 Mycobacterium kansasii Species 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 2
- 206010034811 Pharyngeal cancer Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 101800001494 Protease 2A Proteins 0.000 description 2
- 101800001066 Protein 2A Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000007660 Residual Neoplasm Diseases 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 235000004443 Ricinus communis Nutrition 0.000 description 2
- 240000000528 Ricinus communis Species 0.000 description 2
- 108010084592 Saporins Proteins 0.000 description 2
- 208000032383 Soft tissue cancer Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000005859 cell recognition Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000011961 computed axial tomography Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229940125777 fusion inhibitor Drugs 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000037451 immune surveillance Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 229910052747 lanthanoid Inorganic materials 0.000 description 2
- 150000002602 lanthanoids Chemical class 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical class CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000009126 molecular therapy Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 230000001400 myeloablative effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 229960000237 vorinostat Drugs 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- UFIVODCEJLHUTQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-(1-phenylethyldisulfanyl)-2h-pyridine-1-carboxylate Chemical compound C=1C=CC=CC=1C(C)SSC1C=CC=CN1C(=O)ON1C(=O)CCC1=O UFIVODCEJLHUTQ-UHFFFAOYSA-N 0.000 description 1
- FLCQLSRLQIPNLM-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-acetylsulfanylacetate Chemical compound CC(=O)SCC(=O)ON1C(=O)CCC1=O FLCQLSRLQIPNLM-UHFFFAOYSA-N 0.000 description 1
- VQZYZXLBKBUOHE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)butanoate Chemical compound C=1C=CC=NC=1SSC(C)CC(=O)ON1C(=O)CCC1=O VQZYZXLBKBUOHE-UHFFFAOYSA-N 0.000 description 1
- QFQYGJMNIDGZSG-YFKPBYRVSA-N (2r)-3-(acetamidomethylsulfanyl)-2-azaniumylpropanoate Chemical compound CC(=O)NCSC[C@H]([NH3+])C([O-])=O QFQYGJMNIDGZSG-YFKPBYRVSA-N 0.000 description 1
- FFILOTSTFMXQJC-QCFYAKGBSA-N (2r,4r,5s,6s)-2-[3-[(2s,3s,4r,6s)-6-[(2s,3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(e)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hy Chemical compound O[C@@H]1[C@@H](O)[C@H](OCC(NC(=O)CCCCCCCCCCCCCCCCC)C(O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO)C(O)=O)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 FFILOTSTFMXQJC-QCFYAKGBSA-N 0.000 description 1
- BFNDLDRNJFLIKE-ROLXFIACSA-N (2s)-2,6-diamino-6-hydroxyhexanoic acid Chemical compound NC(O)CCC[C@H](N)C(O)=O BFNDLDRNJFLIKE-ROLXFIACSA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- RQJMOCIAILRHIC-JUUVMNCLSA-N (2s)-2-amino-4-methylpentanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound CC(C)C[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 RQJMOCIAILRHIC-JUUVMNCLSA-N 0.000 description 1
- DWKNTLVYZNGBTJ-IBGZPJMESA-N (2s)-2-amino-6-(dibenzylamino)hexanoic acid Chemical compound C=1C=CC=CC=1CN(CCCC[C@H](N)C(O)=O)CC1=CC=CC=C1 DWKNTLVYZNGBTJ-IBGZPJMESA-N 0.000 description 1
- FNRJOGDXTIUYDE-ZDUSSCGKSA-N (2s)-2-amino-6-[benzyl(methyl)amino]hexanoic acid Chemical compound OC(=O)[C@@H](N)CCCCN(C)CC1=CC=CC=C1 FNRJOGDXTIUYDE-ZDUSSCGKSA-N 0.000 description 1
- WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 1
- WOXWUZCRWJWTRT-UHFFFAOYSA-N 1-amino-1-cyclohexanecarboxylic acid Chemical compound OC(=O)C1(N)CCCCC1 WOXWUZCRWJWTRT-UHFFFAOYSA-N 0.000 description 1
- WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- KNQHBAFIWGORKW-UHFFFAOYSA-N 2,3-diamino-3-oxopropanoic acid Chemical compound NC(=O)C(N)C(O)=O KNQHBAFIWGORKW-UHFFFAOYSA-N 0.000 description 1
- HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
- SGAKLDIYNFXTCK-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=O)NC1=O SGAKLDIYNFXTCK-UHFFFAOYSA-N 0.000 description 1
- YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 1
- FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 1
- VHVGNTVUSQUXPS-UHFFFAOYSA-N 2-amino-3-hydroxy-3-phenylpropanoic acid Chemical compound OC(=O)C(N)C(O)C1=CC=CC=C1 VHVGNTVUSQUXPS-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
- SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
- YXDGRBPZVQPESQ-QMMMGPOBSA-N 4-[(2s)-2-amino-2-carboxyethyl]benzoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(C(O)=O)C=C1 YXDGRBPZVQPESQ-QMMMGPOBSA-N 0.000 description 1
- GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
- CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 1
- GTVVZTAFGPQSPC-UHFFFAOYSA-N 4-nitrophenylalanine Chemical compound OC(=O)C(N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-UHFFFAOYSA-N 0.000 description 1
- MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
- WPYRHVXCOQLYLY-UHFFFAOYSA-N 5-[(methoxyamino)methyl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CONCC1=CNC(=S)NC1=O WPYRHVXCOQLYLY-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- VKLFQTYNHLDMDP-PNHWDRBUSA-N 5-carboxymethylaminomethyl-2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C(CNCC(O)=O)=C1 VKLFQTYNHLDMDP-PNHWDRBUSA-N 0.000 description 1
- ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
- KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
- KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- 101710171728 Abrin-b Proteins 0.000 description 1
- 244000144619 Abrus precatorius Species 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 101000854353 Agrocybe aegerita Ribonuclease ageritin Proteins 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 101150113144 CARTPT gene Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- 108010053406 CRM 107 Proteins 0.000 description 1
- 101100156338 Caenorhabditis elegans vit-4 gene Proteins 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710205625 Capsid protein p24 Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 206010057854 Cerebral Toxoplasmosis Diseases 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 108010037897 DC-specific ICAM-3 grabbing nonintegrin Proteins 0.000 description 1
- 239000012650 DNA demethylating agent Substances 0.000 description 1
- 229940045805 DNA demethylating agent Drugs 0.000 description 1
- 239000012625 DNA intercalator Substances 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 229910052692 Dysprosium Inorganic materials 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000009129 Ear Neoplasms Diseases 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 241000282323 Felidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101000736086 Felis catus PC4 and SFRS1-interacting protein Proteins 0.000 description 1
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 108010002459 HIV Integrase Proteins 0.000 description 1
- 208000031957 HIV carrier Diseases 0.000 description 1
- 208000003577 HIV wasting syndrome Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 description 1
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- VEBVPUXQAPLADL-UHFFFAOYSA-N Ingenol Natural products C1=C(CO)C(O)C2(O)C(O)C(C)=CC32C(C)CC2C(C)(C)C2C1C3=O VEBVPUXQAPLADL-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 102000004559 Interleukin-13 Receptors Human genes 0.000 description 1
- 108010017511 Interleukin-13 Receptors Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- VHVGNTVUSQUXPS-YUMQZZPRSA-N L-threo-3-phenylserine Chemical compound [O-]C(=O)[C@@H]([NH3+])[C@@H](O)C1=CC=CC=C1 VHVGNTVUSQUXPS-YUMQZZPRSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010024291 Leukaemias acute myeloid Diseases 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- 241001441512 Maytenus serrata Species 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241000187722 Micromonospora echinospora Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241001502334 Mycobacterium avium complex bacterium Species 0.000 description 1
- 241000187484 Mycobacterium gordonae Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 229940124821 NNRTIs Drugs 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 102000004459 Nitroreductase Human genes 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 206010030154 Oesophageal candidiasis Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 101710177166 Phosphoprotein Proteins 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241001672814 Porcine teschovirus 1 Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- NUQJULCGNZMBEF-UHFFFAOYSA-N Prostratin Natural products COC(=O)C12CC(C)C3(O)C(C=C(CO)CC4(O)C3C=C(C)C4=O)C1C2(C)C NUQJULCGNZMBEF-UHFFFAOYSA-N 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 108020004422 Riboswitch Proteins 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 206010058878 Salmonella sepsis Diseases 0.000 description 1
- 240000003946 Saponaria officinalis Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 101710149279 Small delta antigen Proteins 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- 230000010782 T cell mediated cytotoxicity Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 239000000061 acid fraction Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000037006 agalactosis Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N aldehydo-D-galactose Chemical group OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- 108010001818 alpha-sarcin Proteins 0.000 description 1
- 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- JINBYESILADKFW-UHFFFAOYSA-N aminomalonic acid Chemical compound OC(=O)C(N)C(O)=O JINBYESILADKFW-UHFFFAOYSA-N 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 201000007696 anal canal cancer Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940124411 anti-hiv antiviral agent Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229950007936 apricitabine Drugs 0.000 description 1
- RYMCFYKJDVMSIR-RNFRBKRXSA-N apricitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1S[C@H](CO)OC1 RYMCFYKJDVMSIR-RNFRBKRXSA-N 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 208000003373 basosquamous carcinoma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229960005520 bryostatin Drugs 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 101150058049 car gene Proteins 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000010039 central nervous system leukemia Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- 208000012191 childhood neoplasm Diseases 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000006690 co-activation Effects 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 201000008167 cystoisosporiasis Diseases 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960005107 darunavir Drugs 0.000 description 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- 239000012649 demethylating agent Substances 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 229940042396 direct acting antivirals thiosemicarbazones Drugs 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- 229960002542 dolutegravir Drugs 0.000 description 1
- RHWKPHLQXYSBKR-BMIGLBTASA-N dolutegravir Chemical compound C([C@@H]1OCC[C@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F RHWKPHLQXYSBKR-BMIGLBTASA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003118 drug derivative Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 1
- 208000031083 ear cancer Diseases 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229960003586 elvitegravir Drugs 0.000 description 1
- JUZYLCPPVHEVSV-LJQANCHMSA-N elvitegravir Chemical compound COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F JUZYLCPPVHEVSV-LJQANCHMSA-N 0.000 description 1
- 238000004993 emission spectroscopy Methods 0.000 description 1
- 229960000366 emtricitabine Drugs 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 229960000980 entecavir Drugs 0.000 description 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 201000005655 esophageal candidiasis Diseases 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229960002049 etravirine Drugs 0.000 description 1
- PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 230000012953 feeding on blood of other organism Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960003142 fosamprenavir Drugs 0.000 description 1
- MLBVMOWEQCZNCC-OEMFJLHTSA-N fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- QNRXNRGSOJZINA-UHFFFAOYSA-N indoline-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)CC2=C1 QNRXNRGSOJZINA-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- VEBVPUXQAPLADL-POYOOMFHSA-N ingenol Chemical compound C1=C(CO)[C@@H](O)[C@]2(O)[C@@H](O)C(C)=C[C@]32[C@H](C)C[C@H]2C(C)(C)[C@H]2[C@H]1C3=O VEBVPUXQAPLADL-POYOOMFHSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229940124525 integrase strand transfer inhibitor Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 230000008095 long lasting therapeutic effect Effects 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000011469 lymphodepleting chemotherapy Methods 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000022924 malignant ear neoplasm Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 description 1
- 229960004710 maraviroc Drugs 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020001162 nitroreductase Proteins 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003865 nucleic acid synthesis inhibitor Substances 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 201000003437 pleural cancer Diseases 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- BOJKFRKNLSCGHY-HXGSDTCMSA-N prostratin Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)C[C@@]3(OC(C)=O)C(C)(C)[C@H]3[C@@H]21 BOJKFRKNLSCGHY-HXGSDTCMSA-N 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960004742 raltegravir Drugs 0.000 description 1
- CZFFBEXEKNGXKS-UHFFFAOYSA-N raltegravir Chemical compound O1C(C)=NN=C1C(=O)NC(C)(C)C1=NC(C(=O)NCC=2C=CC(F)=CC=2)=C(O)C(=O)N1C CZFFBEXEKNGXKS-UHFFFAOYSA-N 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229960002814 rilpivirine Drugs 0.000 description 1
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 1
- 108010091666 romidepsin Proteins 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000007659 semicarbazones Chemical class 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 150000003584 thiosemicarbazones Chemical class 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960000838 tipranavir Drugs 0.000 description 1
- SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000007888 toxin activity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 description 1
- PMMYEEVYMWASQN-IMJSIDKUSA-N trans-4-Hydroxy-L-proline Natural products O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229930013292 trichothecene Natural products 0.000 description 1
- 150000003327 trichothecene derivatives Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- WCNMEQDMUYVWMJ-JPZHCBQBSA-N wybutoxosine Chemical compound C1=NC=2C(=O)N3C(CC([C@H](NC(=O)OC)C(=O)OC)OO)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WCNMEQDMUYVWMJ-JPZHCBQBSA-N 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- C07K14/16—HIV-1 ; HIV-2
- C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/29—Multispecific CARs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Description
本願は、米国特許法第119(e)条に準拠して、2017年12月20日付で提出された米国仮特許出願第62/608,479号、2018年4月20日付で提出された米国仮特許出願第62/660,819号に基づく優先権を主張する。同米国仮特許出願の各々の全記載内容を引用により本明細書に援用する。
本願は、ASCII様式にて電子的に提出された配列表を含み、この配列表の全体を引用により本明細書に援用する。このASCIIのコピー(2018年12月18日作成)のファイル名は「SequenceListing.txt」であり、サイズは232キロバイトである。
該当なし
本開示の分野
本願は、ヒト免疫不全ウイルスによる感染/後天性免疫不全症候群(HIV、HIV/AIDS)に関連する疾患の分野、特にタンパク質結合ドメイン、およびこのような結合ドメインを含有するキメラ抗原受容体(CARs)、およびその使用方法に関する。
ヒト免疫不全ウイルス(HIV)による感染は、依然として、人間の健康にとって大きな脅威である。2016年には、世界中で100万人がHIVに関連する原因で死亡しており、3670万人がHIVを保菌していると推定される。HIV保菌者である成人の54%および子供の43%が、現在、生涯続く抗レトロウイルス薬に基づく療法(ART)を受けている。HIV感染を治癒させる方法はないが、ARTにより、多くの人が実りある生活を長く送れるようになった(データはすべて、WHOファクトシートの2017年7月更新分より)。長期の抗レトロウイルス療法(ART)によって、重症の毒性、ならびにリポジストロフィ、インスリン抵抗性、心血管疾患、および臓器不全などの併存疾患の発生確率が高くなる可能性がある。加えて、長期ARTによって、HIV薬剤耐性および薬効低下が生じる可能性もある。ARTは感染の制御に功を奏してはいるが、治癒法ではない。
新規の抗HIVエンベロープタンパク質抗体、またはその抗原結合ドメイン、およびこのような抗HIVエンベロープタンパク質抗原結合ドメインを含有するキメラ抗原受容体(CARs)、および、この受容体を発現する宿主細胞(たとえば、T細胞)、およびこの受容体をコードする核酸分子が、本明細書中において提供される。このCARは、形質導入T細胞上での表面発現のレベルが高く、細胞溶解の程度が高く、かつ形質導入T細胞がin vivoにおいて増殖および持続できる。さらに、たとえば、患者におけるHIV感染またはAIDSまたはHIV関連がんを処置するための、開示されるCAR、宿主細胞、および核酸分子の使用方法が提供される。
定義
本明細書中において使用される場合、単数形「a」、「an」、および「the」は、文脈上明らかな矛盾がない限り、単数形と複数形の両方を指す。たとえば、用語「an antigen(抗原)」は、1つまたは複数の抗原を含み、「少なくとも1つの抗原」という言葉と同等であるとみなし得る。本明細書中において使用される場合、用語「comprises」は「includes」を意味する。したがって、「comprising an antigen」は、他の要素を除外しない「including an antigen」を意味する。「および/または」という言葉は、「および」または「または」を意味する。さらに、特に記載がない限り、核酸またはポリペプチドに与えられる任意のおよびすべての塩基の大きさまたはアミノ酸の大きさならびにすべての分子量または分子質量の値は、近似値であり、説明目的で提供されることが理解される。本明細書中に記載されるものと類似または同等の多くの方法および材料を使用できるが、特に好適な方法および材料が以下に記載される。万一矛盾がある場合には、本明細書(用語の説明を含む)が支配する。これに加えて、材料、方法、および例示は、例証することのみを目的とし、限定を意図しない。多様な実施形態の確認を容易にするために、以下に用語の説明が提供される。
本明細書中に開示されるCARは、HIVエンベロープタンパク質に結合できる少なくとも1つのHIV抗原結合ドメインと、少なくとも1つの膜貫通ドメインと、少なくとも1つの細胞内ドメインとを含む。
一実施形態において、CARは、抗原結合ドメインまたは部位とも称される標的特異的結合要素を含む。ドメインの選択は、標的細胞の表面を定めるリガンドの種類および数に依存する。たとえば、抗原結合ドメインは、特定の疾患状態に関連する標的細胞上において細胞表面マーカーとして働くリガンドを認識するように選択されてよい。したがって、CARにおける抗原結合ドメインのリガンドとして働き得る細胞表面マーカーの例は、ウイルス感染、細菌感染、および寄生虫感染、自己免疫疾患、およびがん細胞に関連するものを含む。
膜貫通ドメインに関して、CARは、当該CARの細胞外のmD1.22およびm36.4抗原結合ドメインに融合した1つ以上の膜貫通ドメインを含む。
CARにおいて、細胞外ドメインと膜貫通ドメインとの間、または細胞内ドメインと膜貫通ドメインとの間に、スペーサドメインが配置されていてよい。スペーサドメインとは、膜貫通ドメインを細胞外ドメインと、および/または膜貫通ドメインを細胞内ドメインと結合させるように働く、任意のオリゴペプチドまたはポリペプチドを意味する。スペーサドメインは、アミノ酸上限300個まで、好ましくはアミノ酸10~100個、最も好ましくはアミノ酸25~50個を含む。
CARの細胞質ドメインまたは細胞内シグナル伝達ドメインは、CARが導入された免疫細胞の正常なエフェクター機能のうち少なくとも1つの活性化を担う。用語「エフェクター機能」は、細胞の特殊機能を指す。たとえば、T細胞のエフェクター機能は、細胞溶解活性、またはサイトカインの分泌を含むヘルパー活性であり得る。よって、用語「細胞内シグナル伝達ドメイン」は、エフェクター機能シグナルを伝達し細胞が特殊機能を果たすように仕向ける、タンパク質部分を指す。通常は細胞内シグナル伝達ドメインの全体を使用できるが、多くの場合、鎖全体を使用する必要はない。細胞内シグナル伝達ドメインを切断した一部が使用される場合、この切断部分がエフェクター機能シグナルを伝達できる限りは、これを完全な鎖の代わりに使用してよい。したがって、用語「細胞内シグナル伝達ドメイン」の意味には、エフェクター機能シグナルを伝達するのに十分な細胞内シグナル伝達ドメインの任意の切断部分が含まれる。
本明細書中に開示されるCARの機能的部分もまた、本発明の範囲内に明白に含まれる。用語「機能的部分」は、CARに言及して使用される場合、本明細書中に開示されるCARの1種以上の任意の部分または断片を指し、この部分または断片は、当該CAR(親CAR)の生物学的活性を保持する。機能的部分は、たとえば、親CARと類似する程度に、親CARと同程度に、または親CARよりも高程度に、標的細胞の認識、または疾患の検出、処置、もしくは予防を行なう能力を保持する、CAR部分を包含する。親CARに関して、機能的部分は、たとえば、親CARの約10%、25%、30%、50%、68%、80%、90%、95%、またはそれ以上を含み得る。
一実施形態は、本明細書中に開示される抗原の1つ以上に特異的に結合する、CAR、CARを発現するT細胞、抗体、またはその抗原結合ドメインもしくは一部分をさらに提供する。本明細書中において使用される場合、「CARを発現するT細胞」または「CAR T細胞」または「CAR-T」は、CARを発現するT細胞を意味し、たとえばCARの抗体由来標的ドメインによって決定される、抗原特異性を有する。
本明細書中に開示される抗原の1つ以上に対して特異的な、CAR、CARを発現するT細胞、またはモノクローナル抗体、またはその抗原結合断片は、当業者に周知の多くの手段のうち任意の手段を使用して、エフェクター分子または検出可能なマーカーなどの剤に結合されていてよい。共有結合による手段および非共有結合による手段のいずれを使用してもよい。結合体は、本明細書中に開示される抗原の1つ以上に対して特異的に結合する抗体または抗原結合断片と、エフェクター分子または検出可能なマーカーとが共有結合している分子を含むが、これらに限定されない。当技術分野における当業者には、抗ウイルス剤、抗微生物剤、化学療法剤、抗血管新生剤、毒素、125I、32P、14C、3H、および35Sなどの放射性剤、ならびに、他の標識、標的部位、およびリガンドなどを含む(がこれらに限定されない)多様なエフェクター分子および検出可能なマーカーを使用できるということが理解される。
本発明の一実施形態によって、本明細書中に記載されるCAR、抗体、またはその抗原結合部分(その機能的部分および機能的バリアントを含む)のうち任意のものをコードするヌクレオチド配列を含む核酸がさらに提供される。本発明に係る核酸は、本明細書中に記載されるリーダー配列、抗原結合ドメイン、膜貫通ドメイン、および/または細胞内T細胞シグナル伝達ドメインのうち任意のものをコードするヌクレオチド配列を含んでよい。
本明細書中に開示されるCARを哺乳動物におけるHIV/AIDSの処置または予防方法において使用してよいことが意図される。この点において、一実施形態は、哺乳動物におけるHIV/AIDSの処置または予防方法を提供し、これは、哺乳動物に、CAR、核酸、組換え発現ベクター、宿主細胞、細胞の集団、抗体および/またはその抗原結合部分、および/または医薬組成物を、哺乳動物におけるHIV-1感染および/またはAIDSの処置または予防に有効な量にて投与する工程を含む。
本明細書中に開示される1つ以上の抗原に特異的に結合する、開示されるCAR、またはCARを発現するT細胞、抗体、抗原結合断片、結合体、CAR、またはCARを発現するT細胞のうち1種以上を、担体(製薬学的に許容される担体など)中に含む、バイオ医薬組成物または生物組成物(以下、「組成物」)が、本明細書中において、遺伝子療法、免疫療法、および/または細胞療法における使用を目的として提供される。この組成物は、対象への投与のために単位投薬形態にて調製されてよい。投与の量およびタイミングは、所望される転帰を達成するために、処置担当臨床医によって判断される。この組成物は、全身(静脈内など)または局所(臓器内など)への投与を目的として配合されてよい。一例において、開示されるCAR、またはCARを発現するT細胞、抗体、抗原結合断片、結合体は、静脈内投与などの非経口投与を目的として配合される。本明細書中に開示されるCAR、またはCARを発現するT細胞、結合体、抗体、または抗原結合断片を含む組成物は、たとえば、感染症(たとえば、HIV-1感染であるが、これに限定されない)の処置および検出に有用である。本明細書中に開示されるCAR、またはCARを発現するT細胞、結合体、抗体、または抗原結合断片を含む組成物は、たとえば免疫機能不全の検出にも有用である。
一態様において、本明細書中に開示されるCARを使用するキットがさらに提供される。たとえば、対象におけるHIV/AIDSを処置するための、または本明細書中に開示されるCARの1種以上を発現するCAR T細胞を作製するためのキットである。こうしたキットは、典型的には、本明細書中に開示される抗体、抗原結合断片、結合体、核酸分子、CAR、またはCARを発現するT細胞を含んでよい。開示される抗体、抗原結合断片、結合体、核酸分子、CAR、またはCARを発現するT細胞のうち1種を超えるものが、キット中に含まれてよい。
本発明が、以下の実施例によってさらに例証されるが、これらの実施例は、本発明の範囲を限定すると解釈されるべきではない。逆に、様々な他の実施形態、改変、および等価物に頼らなければならず、こうした他の実施形態、改変、および等価物は、本発明の精神および/または付属の請求項の範囲から逸脱することなく、本明細書の記載を読んだ後、当業者の念頭に浮かび得るということが明瞭に理解される。
この実施例は、mD1.22、m36.4、およびC46ペプチドを含有する単一特異性、二重特異性、および三重特異性抗HIV CARの一般的な構築方法と、こうしたCARを一次T細胞の表面にどのように発現させるかとを記載する。
レンチウイルスベクターコンストラクトの作製
CAR抗原結合ドメイン配列は、発表されている配列に由来するもの(Chenら,J.Virol.2014;88:(2)1125-1139;Chenら,Antiviral Research 2010;88:(1)107-115;Egererら,Molecular Therapy 2010;19:(7)1236-1244)、および、ATUM(旧社名はDNA 2.0;Newark、CA)またはIDT Technologies(Coralville、IA)により合成されたものであった。合成された遺伝子断片を、CD8リンカー/ヒンジ、CD8膜貫通ドメイン、41-BB、およびCD3ゼータシグナル伝達ドメインを含有する、MSCVプロモーターに基づくレンチウイルスのバックボーンに、インフレームにてサブクローニングした。バイシストロニックな二重特異性および三重特異性CARコンストラクトのために、切断可能なフーリン-P2A-フーリン部位を、1つのまたは2つ結合した抗原結合ドメインを含有する第1のCARの下流に配置し、その後に、第3の抗原結合ドメイン、CD8リンカー/ヒンジ、TNFRSF19膜貫通部、および任意にCD3ゼータシグナル伝達ドメインを配置した。配列およびCAR構造についての詳細な説明が、以下に、表1中に示される。このDNAコンストラクトをサンガーシーケンシングによって確認した(GeneWiz、South Plainfield、NJ)。Clone Managerソフトウェア(Denver、CO)を使用して、プラスミドマッピングを作製した。
ポリエチレンイミン(PEI)の存在下、4つのプラスミドを使用するシステムを用いて、293T浮遊細胞を一過性トランスフェクションすることによって、CAR導入遺伝子を有するレンチウイルスベクターを作製した。簡潔には、CARトランスファープラスミド、VSVgエンベロープ、gag/pol、およびrevプラスミドを用いて浮遊293Tをコトランスフェクションし、続いて16時間後に培養物に酪酸ナトリウムを添加した。48時間後、レンチウイルスベクターを含有する上清(400mL以下)を、10,000×gにて一晩、少なくとも18時間にわたって超遠心して、濃縮した。5.96mM HEPES、5%トレハロース、および100mM NaClを含有するろ過滅菌SECバッファー2mL中にペレットを再懸濁して、穏やかな撹拌によりペレットを容易に溶解させた。再懸濁させたレンチウイルス粒子を、後に使用するまで、複数のアリコートとして-80℃で保管した。
細胞約1×106個をMACSバッファー(10%ウシ血清アルブミンを含有するリン酸塩緩衝生理食塩水、pH7.2以下)中で洗浄した。次いで、Vioblue標識CD4抗体(クローンVIT4)およびFITC標識CD8抗体を、製造元の説明書(Miltenyi Biotec)にしたがって細胞に添加した。4℃において30分間インキュベートした後、細胞をMACSバッファー中で2回洗浄し、0.2mLのMACSバッファー中に再懸濁した。C46ペプチドを含有するCARを検出するために、組換えヒトモノクローナル抗体2F5(Polymun Scientific、Klosterneuburg、オーストリア)を、希釈率1:1000にて、4℃において30分間かけて添加し、続いてMACSバッファー中で2回洗浄した。2F5は、C46ペプチド中に見られるエピトープELDKWAを認識する。次いで、細胞をFITC標識F(ab’)2抗ヒトIgGと共に4℃において30分間インキュベートし、2回洗浄し、次いで0.2mLのMACSバッファー中に再懸濁した。MACS Quant VYB1血球計(Miltenyi Biotec)を使用してフローサイトメトリーを行ない、FlowJoソフトウェア(Tree Star、Ashland、OR)を使用して分析を行なった。
概して、抗HIV CARは、レンチウイルスベクターを使用した遺伝子改変が70%までの範囲において、一次T細胞の表面に高発現していた。図3Aおよび図3B中に示すように、mD1.22ドメイン(LTG1944)、m36.4ドメイン(LTG1945)、またはC46ペプチド(LTG2328)のいずれかを含有する単一特異性CARは、T細胞の表面に機能的に発現していた。CD3ゼータシグナル伝達ドメイン上流に細胞内mCherryレポーターを融合させることによって、m36.4 CARが間接的に検出された(図3B)。
この実施例は、高感受性のルシフェラーゼに基づく細胞毒性アッセイによって判断した抗HIV CARの機能的特徴づけを記載する。加えて、T細胞の活性化を、HIVエンベロープ発現標的細胞の存在下および非存在下におけるサイトカイン分泌を定量することによって判断する。
機能的特徴づけに使用した細胞株
一本鎖全長HIVエンベロープタンパク質(293T-Env)を安定して発現するように操作された293T細胞株は、Dimiter Dimitrov博士(NCI、Fort Detrick、MD)の厚意により提供されたものである。簡潔には、293T-Env細胞を、10%ウシ胎児血清と、選択維持のためのゼオシン60μg/mlとの存在下において、ダルベッコ改変イーグル培地(DMEM)中で増殖させた。ルシフェラーゼ発現細胞を発生させるために、ホタルルシフェラーゼ遺伝子を含有するレンチウイルスベクターを用いて293T-Env細胞を形質導入し、シングルセルクローニングを行ない、293T細胞の表面におけるgp120/gp41の発現(2G12、b12、および2F5フローサイトメトリーにより)およびルシフェラーゼ活性の両方について試験した。高発現した1つのHIV-1エンベロープおよびルシフェラーゼクローンを単離して、本明細書中に記載される細胞毒性アッセイにおいて使用した(293T-Env-Luc)。エンベロープ非含有細胞株として、Raji細胞および293T HEK細胞をATCC(Manassas、VA)から購入し、続いて、ホタルルシフェラーゼ遺伝子をコードするレンチウイルスベクターを用いて形質導入して、Raji-Luc細胞株または293T-Luc細胞株をそれぞれ発生させた。Raji-Luc細胞は、10%ウシ胎児血清を含有するRPMI培地中において維持した。293T-Luc細胞は、10%ウシ胎児血清を含有するDMEM培地中において維持した。両細胞株について、シングルセルクローニングを行ない、2G12、b12、および2F5(HIV-1エンベロープに対するモノクローナル抗体)を用いたフローサイトメトリー分析によって、HIVエンベロープが存在しないことを確認した。
ficoll-paque勾配分離とleucosep管とを組み合わせて使用して、健康な志願者からのヒトPBMCをバフィーコートから精製し、続いて、CD4+およびCD8+ T細胞の免疫磁気ビーズ選択を製造元のプロトコールのとおりに行なった(Miltenyi Biotec、Bergisch-Gladbach、ドイツ)。0日目に、40IU/mL IL-2(Miltenyi Biotec)の存在下において、CD3/CD28 MACS(登録商標)Large-scale T Cell TransAct試薬(Miltenyi Biotec)を用いて、T細胞を活性化した。3日目に、活性化させたT細胞を、CARコンストラクトをコードするレンチウイルスベクターを用いて、10μg/mlプロタミン硫酸塩(Sigma-Aldrich、St.Louis、MO)および200IU/mL IL-2の存在下において形質導入した。200IU/ml IL-2を添加したTexMACS培地中において培養物を増殖させ、9~10日目に、機能的分析のために回収した。
簡潔には、滅菌96ウェルプレート中において、ホタルルシフェラーゼを安定して発現する標的細胞5×103個を、多様なエフェクター標的比にてCAR T細胞と組み合わせて、または組み合わせずに、37℃において一晩、5% CO2の存在下にてインキュベートした。24時間後、100μLのSteadyGlo試薬(Promega、Madison WI)を各ウェルに添加して、室温で10分間インキュベートし、続いて、Enspireプレートリーダー(Perkin Elmer、Waltham、MA)を使用して発光を定量した。発光を、指定のE:T比(試料CPS)および標的細胞単独(標的CPS)を含有する各実験ウェルについて、1秒あたりのカウント(CPS)として記録した。特異的溶解の割合を、1-(試料CPS/標的CPS)として計算した。
細胞毒性アッセイからの上清を回収して(E:T比 10:1)、10倍希釈し、Ready-Set-Go ELISAを用いて製造元の説明書のとおりに(eBioscience、San Diego、CA)、IFN-γおよびIL-2についてアッセイした。
HIVエンベロープタンパク質は、HIVウイルス粒子の表面に発現されるヘテロ三量体糖タンパク質であり、T細胞を標的化およびハイジャックするために使用される。HIV感染が生じている間、HIVエンベロープタンパク質(gp120)はヘルパーT細胞のCD4受容体に結合して、HIVエンベロープタンパク質のコンフォメーションの変化を導く。この変化によって、指向性依存的に、T細胞の表面上の共受容体(たとえば、CCR5またはCXCR4)との相互作用が促進され、最終的に、ウイルス融合が生じ、続いてT細胞に対してHIVウイルスRNAの細胞内放出が生じる。続いて、ウイルスRNAが逆転写されて宿主ゲノムに組み込まれ、その中で感染性ウイルスをさらに産生し得る、または潜伏状態となり得る。T細胞がHIVウイルスを活発に産生している間、こうした感染T細胞の表面上に、ウイルス出芽の結果としてHIVエンベロープタンパク質(gp120/gp41)の一部が残る。よって、HIVエンベロープ糖タンパク質を認識するよう設計したCARにより、増殖性HIV感染細胞を特異的に標的とし、続いて、その設計の効によって、こうしたHIV感染細胞を除去することができる。
この実施例では、異なるEnv-IMC-LucR HIV-1ウイルスに感染させたPBMCを用いたin vitroおよびin vivo曝露における、抗HIV CAR-T細胞の死滅効力と、CAR-T細胞のHIV-1感染感受性とを調べる。
複製可能Env-IMC-LucR分子クローンを使用して、ドナーが同じであるPBMCに感染させた際の、in vitroにおける抗HIV CARの効力
インフレームのウミシイタケルシフェラーゼORFの上流に所望の異種HIV-1エンベロープを含有する複製可能HIV-1分子クローン(Env-IMC-LucR)を使用して、HIV-1感染の阻害について調べた。感染性のクローンを、以前に記載されるとおりに作製した(Edmondsら,Virology 2010,408:1-13)。PBMCまたはCD4+ T細胞のHIV-1感染にあたり、接種後、長くて数週間の間、ウミシイタケルシフェラーゼの発現を、高感受性かつ定量可能なHIV-1ウイルス複製指標として使用する。簡潔には、自己由来ドナーPBMC(HIV-1ナイーブ)を、PHA(4μg/mL)およびIL-2(100U/mL)を使用して活性化し、37℃において、R10培地(10%熱失活FBS、ペニシリン(100U/mL)、ストレプトマイシン(10μg/mL)、グルタミン(2mM)、およびHEPES(10mM)を添加したRPMI)中で培養した。1日後、96ウェル丸底プレート中において、24時間かけて、1×105個のPBMCを、指定のEnv-IMC-LucRウイルス1×105IU/mL(MOI=1)に感染させた。翌日、感染PBMCに1×105個のエフェクター細胞(抗HIV CAR T細胞)を添加して、7日間共培養した。in vitro保護アッセイのために、PBMCの非存在下において、抗HIV CAR-Tエフェクターを指定のEnv-IMC-LucRウイルスにMOI=1において直接曝露した。0、3、5、および7日目に共培養物から細胞培養上清(60μL)を回収してさらなる分析に供し、培養物にはR10培地を補充した。7日後、細胞をペレット状に沈殿させて、溶解バッファー20μLを用いて溶解させ、製造元の説明書(Promega、Madison、WI)のとおりに発光を定量した(相対発光量、RLU)。3つの独立したドナーを使用してデータを得た(エラーバー=標準偏差)。製造元の説明書にしたがって、ルシフェラーゼ活性を定量した。データは相対発光量(RLU)で表した。in vitro死滅アッセイのために、HIV-1感染のlog阻害を、式「(HIV-1感染のlog阻害)=Log10(CARRLU/UTDRLU)」を用いて計算した。HIV-1阻害の割合を、1-(CARRLU/UTDRLU)×100%により計算した。統計学的分析は、in vitro死滅効力アッセイでは多重分析スチューデントt検定を用い、in vitro保護アッセイでは一方向ANOVAを用いて行なった。
以前に記載されるとおりに(Bardhiら,J Virol 2017,91:20;Thomasら,Methods Mol Bio 2016,1354:221-35)、Env-IMC-LucR HIV-1ウイルスに感染させたヒトPBMCを用いてマウス脾臓内にて迅速かつ強力かつ容易に定量可能なHIV-1感染を確立したヒト化脾臓内NOD-SCID-IL2Rγ-/-マウスモデル(hu-spl-PBMC-NSG)を使用して、in vivoにおける抗HIV duoCAR-T細胞の効力を調べた。簡潔には、ドナーが同じであるPBMCを1000万個、上述されるとおりに活性化して、107個のPBMCにつきDu422.1を106IU用いてスピンフェクト(spinfect)した。HIVに感染したPBMCを、非形質導入T細胞(UTD)、またはCAR含有T細胞を30~50%含有するLTG2303(二重特異性duoCAR)もしくはLTG2330(三重特異性duoCAR)のいずれかと共に、E:T比0.5:1(たとえば、CAR-T細胞を総数500万個とHIV感染PBMCを1000万個)にて、脾臓内に注入した。PBMCと、CARエフェクター細胞を含有するT細胞とは、注射直前に混合した。感染させて1週間(急性)または1か月(慢性)後に、マウスを犠牲死させ、さらなる分析のために脾臓を回収した。全脾細胞を3つの群に分けて、以下のアッセイを行なった:1)感染を測定するためのルシフェラーゼアッセイ、2)CD4+およびCD8+ T細胞を検出するためのフローサイトメトリー解析、ならびに3)実験の最後に、CAR-T細胞の持続性を正確に検出するためのqPCRによるDNA抽出。以前に記載されたとおりに(Seayら,Journal of Virology 2015)、ウミシイタケルシフェラーゼアッセイシステム(Promega、Madison、WI)を使用して、一部の脾細胞についてHIV-1感染を定量した。
簡潔には、100万個のマウス脾細胞を回収し、ACGT社(Germantown、MD)によりPromega Maxwell(登録商標)16 LEV Blood DNA Kitを使用してゲノムDNAを抽出した。CAR-Tの持続性を判断するために、HIV-1ウイルスではなく抗HIV CARのレンチウイルスベクターバックボーン中に含有される固有の断片(c-frag)を使用して、マウス脾細胞から単離したゲノムDNA 50ngあたりのコピー数を調べた。以下のプライマーおよびプローブを使用してc-fragを検出した:フォワードプライマー 5’GGAGTTGAGACCAGTGTAGT-3’、リバースプライマー 5’-CCACTCCTGACAACTACTCT-3’、プローブ 5’-FAM-CAGTAGGTGAAGGAGTCGTAGTTG-TAMRA-3’。以下のプライマーおよびプローブを使用して、PCR阻害のために制御するためにポリピリミジントラクト結合タンパク質2(PTBP2)遺伝子を検出した:フォワードプライマー 5’-TCTCCATTCCCTATGTTCATGC-3’、リバースプライマー 5’-GTTCCCGCAGAATGGTGAGGTG-3’、プローブ 5’-JOEATGTTCCTCGGACCAACTTG-BHQ-1-3’。c-frag遺伝子タグを含有するプラスミドDNAの周知の量からなる検量線を使用し、続いて、1回のPCR反応あたりの試料体積(12.5μL)の乗算により、インプットした脾臓DNA(0.05μg)に標準化することによって、脾臓DNA中のcFragのコピー数を計算した。
HIV免疫療法の分野における大きな課題は、HIVを正確に標的化して制御してウイルスエスケープを予防できる療法の開発である。併用抗レトロウイルス療法と同様に、免疫療法アプローチを使用してHIVエンベロープを標的とする複数の方法によれば、HIV感染を良好に制御でき、かつ、現行の薬物療法では解決できていない問題である潜伏HIVリザーバーの標的化も行なえるという利点も得られる。このような免疫療法を効果的に開発するためには、HIVエンベロープタンパク質上で高度に保存されている複数の重複しないエピトープを標的とする必要があると考えられ、これにより、ウイルスエスケープ時におけるウイルス適応性を低下傾向とし得る。この目的のために、HIV-1ウイルスの侵入(mD1.22)、共受容体使用(m36.4)、および融合(C46)に関与する重要な段階に必要とされる高度保存領域を標的とするドメインを用いて二重特異性CARを設計した。二重特異性CARの機能はバインダ構造に関するため、前者を支配する法則を用いることにより、三重特異性CARの合理的設計が可能となった。本明細書中において、網羅的に見いだされるenv遺伝子をコードする遺伝学的に多様でありかつ耐性を有するEnv-IMC-LucR HIV-1ウイルスに対する二重特異性および三重特異性抗HIV CARのin vitroおよびin vivoにおける効力が記載される。これに加えて、m36.4ドメインおよびC46ペプチドについても、in vitroにおいて抗HIV CARを保護する能力について評価し、最も効力の高い抗HIV CARのみをin vivoにおける効力について評価した。
以下に列記される核酸およびアミノ酸配列は、37C.F.R.1.822で規定されるように、ヌクレオチド塩基の標準的な文字省略およびアミノ酸の3文字コードを使用して示される。各核酸配列について一方の鎖のみが示されるが、示された鎖に言及する場合にはその相補鎖が含まれることが理解される。付属の配列表において:
配列番号1は、HIVエンベロープ特異的バインダmD1.22の核酸配列である:
AAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGG
配列番号2は、HIVエンベロープ特異的バインダmD1.22のアミノ酸配列である:
KKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVG
配列番号3は、HIVエンベロープ特異的バインダm36.4の核酸配列である:
CAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA
配列番号4は、HIVエンベロープ特異的バインダm36.4のアミノ酸配列である:
QVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSS
配列番号5は、HIVエンベロープ特異的バインダC46の核酸配列である:
TGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTC
配列番号6は、HIVエンベロープ特異的バインダC46のアミノ酸配列である:
WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF
配列番号7は、CD8膜貫通ドメインの核酸配列である:
ATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGC
配列番号8は、CD8膜貫通ドメインのアミノ酸配列である:
IYIWAPLAGTCGVLLLSLVITLYC
配列番号9は、CD8リンカー/ヒンジドメインの核酸配列である:
ACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGAT
配列番号10は、CD8リンカー/ヒンジドメインのアミノ酸配列である:
TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD
配列番号11は、CD8リンカー/ヒンジ/CD8膜貫通ドメインの核酸配列である:
ACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGC
配列番号12は、CD8リンカー/ヒンジ/CD8膜貫通ドメインのアミノ酸配列である:
TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYC
配列番号13は、TNFRSF19膜貫通ドメインの核酸配列である:
GATACCGCACTGGCGGCCGTGATCTGTAGCGCCCTGGCCACCGTGCTGCTGGCGCTGCTCATCCTTTGCGTGATCTACTGCAAGCGGCAG
配列番号14は、TNFRSF19膜貫通ドメインのアミノ酸配列である:
DTALAAVICSALATVLLALLILCVIYCKRQ
配列番号15は、TNFRSF19膜貫通ドメイン(TNFRSF19TM)ドメインに結合しているCD8リンカーの核酸配列である:
CCGGCTCCACGACCACCCACTCCAGCCCCAACGATTGCGAGCCAACCTCTCAGTCTTCGGCCCGAGGCTTGCAGGCCAGCCGCAGGAGGAGCAGTGCACACCCGAGGACTGGATTTCGATACCGCACTGGCGGCCGTGATCTGTAGCGCCCTGGCCACCGTGCTGCTGGCGCTGCTCATCCTTTGCGTGATCTACTGCAAGCGGCAG
配列番号16は、TNFRSF19膜貫通ドメイン(TNFRSF19TM)ドメインに結合しているCD8リンカーのアミノ酸配列である:
PAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFDTALAAVICSALATVLLALLILCVIYCKRQ
配列番号17は、4-1BBシグナル伝達ドメイン(41BB)の核酸配列である:
AAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTG
配列番号18は、4-1BBシグナル伝達ドメイン(41BB)のアミノ酸配列である:
KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL
配列番号19は、CD3ゼータシグナル伝達ドメイン(CD3ゼータ)の核酸配列である:
CGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGG
配列番号20は、CD3ゼータシグナル伝達ドメイン(CD3ゼータ)のアミノ酸配列である:
RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
配列番号21は、代替配列であるCD3ゼータシグナル伝達ドメイン(CD3ゼータ2)の核酸配列である:
CGGGTTAAATTCTCCCGCAGCGCAGACGCACCCGCCTACCAGCAAGGACAGAATCAGCTCTACAACGAACTGAACCTTGGTAGGAGAGAAGAATATGATGTTCTCGACAAGCGCAGAGGGAGAGATCCAGAGATGGGTGGGAAGCCGCAACGCCGGAAAAACCCACAAGAGGGACTGTACAATGAATTGCAGAAAGATAAGATGGCCGAGGCTTACTCAGAAATCGGAATGAAGGGGGAGCGGCGGAGGGGCAAGGGACATGATGGTCTCTACCAAGGGCTTTCAACCGCTACTAAGGACACTTATGACGCACTCCACATGCAGGCGCTGCCTCCGCGA
配列番号22は、代替配列であるCD3ゼータシグナル伝達ドメイン(CD3ゼータ2)のアミノ酸配列である:
RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
配列番号23は、リンカードメインL1の核酸配列である:
GGCGGAGGCGGGTCA
配列番号24は、リンカードメインL1のアミノ酸配列である:
GGGGS
配列番号25は、リンカードメインL2の核酸配列である:
GGCGGAGGCGGGTCAGGTGGCGGTGGTAGT
配列番号26は、リンカードメインL2のアミノ酸配列である:
GGGGSGGGGS
配列番号27は、リンカードメインL3の核酸配列である:
GGAGGTGGCGGTTCAGGCGGAGGGGGGAGTGGAGGTGGGGGAAGC
配列番号28は、リンカードメインL3のアミノ酸配列である:
GGGGSGGGGSGGGGS
配列番号29は、リンカードメインL4の核酸配列である:
GGCGGAGGCGGGTCAGGTGGCGGTGGTAGTGGCGGTGGCGGTTCAGGCGGTGGTGGGAGT
配列番号30は、リンカードメインL4のアミノ酸配列である:
GGGGSGGGGSGGGGSGGGGS
配列番号31は、リンカードメインLの核酸配列である5:
GGCGGAGGCGGGTCAGGTGGCGGTGGTAGTGGCGGTGGCGGTTCAGGCGGTGGTGGGAGTGGGGGAGGAGGCAGC
配列番号32は、リンカードメインL5のアミノ酸配列である:
GGGGSGGGGSGGGGSGGGGSGGGGS
配列番号33は、リンカーおよび切断部位ドメインFurin-2A-Furin(F2AF)の核酸配列である:
CGCGCGAAACGCAGCGGCAGCGGCGCGACCAACTTTAGCCTGCTGAAACAGGCGGGCGATGTGGAAGAAAACCCGGGCCCGCGAGCAAAGAGG
配列番号34は、リンカーおよび切断部位ドメインFurin-2A-Furin(F2AF)のアミノ酸配列である:
RAKRSGSGATNFSLLKQAGDVEENPGPRAKR
配列番号35は、GMCSFR由来のリーダーペプチド(LP)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACC
配列番号36は、GMCSFR由来のリーダーペプチド(LP)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDT
配列番号37は、CD59由来のリーダーペプチド(LP2)の核酸配列である:
ATGGGAATTCAGGGGGGTTCCGTGCTCTTTGGCTTGCTCCTGGTCCTGGCAGTGTTTTGTCACTCGGGACACAGCCTGCAG
配列番号38は、CD59由来のリーダーペプチド(LP2)のアミノ酸配列である:
MGIQGGSVLFGLLLVLAVFCHSGHSLQ
配列番号39は、抗HIV CAR LTG1944(LP-mD1.22-CD8TM-41BB-CD3ゼータ)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACCAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGGGCGGCCGCAACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGGTAG
配列番号40は、抗HIV CAR LTG1944(LP-mD1.22-CD8TM-41BB-CD3ゼータ)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDTKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
配列番号41は、抗HIV CAR LTG1945(LP-m36.4-CD8TM-41BB-CD3ゼータ)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACCCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGCGGCCGCAACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGGTAG
配列番号42は、抗HIV CAR LTG1945(LP-m36.4-CD8TM-41BB-CD3ゼータ)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDTQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSSAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
配列番号43は、抗HIV CAR LTG2328(LP-C46-CD8TM-41BB-CD3ゼータ)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACCTGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTCGCGGCCGCAACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGGTAG
配列番号44は、抗HIV CAR LTG2328(LP-C46-CD8TM-41BB-CD3ゼータ)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
配列番号45は、LTG2325中に含有される結合した抗HIVバインダ(mD1.22-L1-m36.4)の核酸配列である:
AAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGGCGGAGGCGGGTCACAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA
配列番号46は、CAR LTG2325中に含有される結合した抗HIVバインダ(mD1.22-L1-m36.4)のアミノ酸配列である:
KKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGGGGGSQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSS
配列番号47は、抗HIV CAR LTG2325(LP-mD1.22-L1-m36.4-CD8TM-41BB-CD3ゼータ)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACCAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGGCGGAGGCGGGTCACAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGCGGCCGCAACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGGTAG
配列番号48は、抗HIV CAR LTG2325(LP-mD1.22-L1-m36.4-CD8TM-41BB-CD3ゼータ)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDTKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGGGGGSQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSSAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
配列番号49は、CAR LTG2313中に含有される結合した抗HIVバインダ(mD1.22-L2-m36.4)の核酸配列である:
AAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGGAGGTGGCGGTTCAGGCGGAGGGGGGAGTCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA
配列番号50は、CAR LTG2313中に含有される結合した抗HIVバインダ(mD1.22-L2-m36.4)のアミノ酸配列である:
KKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGGGGGSGGGGSQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSS
配列番号51は、抗HIV CAR LTG2313(LP-mD1.22-L2-m36.4-CD8TM-41BB-CD3ゼータ)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACCAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGGAGGTGGCGGTTCAGGCGGAGGGGGGAGTCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGCGGCCGCAACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGGTAG
配列番号52は、抗HIV CAR LTG2313(LP-mD1.22-L2-m36.4-CD8TM-41BB-CD3ゼータ)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDTKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGGGGGSGGGGSQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSSAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
配列番号53は、LTG1946中に含有される結合した抗HIVバインダ(mD1.22-L3-m36.4)の核酸配列である:
AAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGGAGGTGGCGGTTCAGGCGGAGGGGGGAGTGGAGGTGGGGGAAGCCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA
配列番号54は、LTG1946中に含有される結合した抗HIVバインダ(mD1.22-L3-m36.4)のアミノ酸配列である:
KKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGGGGGSGGGGSGGGGSQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSS
配列番号55は、抗HIV CAR LTG1946(LP-mD1.22-L3-m36.4-CD8TM-41BB-CD3ゼータ)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACCAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGGAGGTGGCGGTTCAGGCGGAGGGGGGAGTGGAGGTGGGGGAAGCCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGCGGCCGCAACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGGTAG
配列番号56は、抗HIV CAR LTG1946(LP-mD1.22-L3-m36.4-CD8TM-41BB-CD3ゼータ)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDTKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGGGGGSGGGGSGGGGSQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSSAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
配列番号57は、LTG2326中に含有される結合した抗HIVバインダ(mD1.22-L4-m36.4)の核酸配列である:
AAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGGCGGAGGCGGGTCAGGTGGCGGTGGTAGTGGCGGTGGCGGTTCAGGCGGTGGTGGGAGTCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA
配列番号58は、LTG2326中に含有される結合した抗HIVバインダ(mD1.22-L4-m36.4)のアミノ酸配列である:
KKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGGGGGSGGGGSGGGGSGGGGSQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSS
配列番号59は、抗HIV CAR LTG2326(LP-mD1.22-L4-m36.4-CD8TM-41BB-CD3ゼータ)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACCAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGGCGGAGGCGGGTCAGGTGGCGGTGGTAGTGGCGGTGGCGGTTCAGGCGGTGGTGGGAGTCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGCGGCCGCAACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGGTAG
配列番号60は、抗HIV CAR LTG2326(LP-mD1.22-L4-m36.4-CD8TM-41BB-CD3ゼータ)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDTKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGGGGGSGGGGSGGGGSGGGGSQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSSAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
配列番号61は、LTG1947中に含有される結合した抗HIVバインダ(mD1.22-L5-m36.4)の核酸配列である:
AAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGGCGGAGGCGGGTCAGGTGGCGGTGGTAGTGGCGGTGGCGGTTCAGGCGGTGGTGGGAGTGGGGGAGGAGGCAGCCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA
配列番号62は、LTG1947中に含有される結合した抗HIVバインダ(mD1.22-L5-m36.4)のアミノ酸配列である:
KKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGGGGGSGGGGSGGGGSGGGGSGGGGSQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSS
配列番号63は、抗HIV CAR LTG1947(LP-mD1.22-L5-m36.4-CD8TM-41BB-CD3ゼータ)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACCAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGGCGGAGGCGGGTCAGGTGGCGGTGGTAGTGGCGGTGGCGGTTCAGGCGGTGGTGGGAGTGGGGGAGGAGGCAGCCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGCGGCCGCAACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGGTAG
配列番号64は、抗HIV CAR LTG1947(LP-mD1.22-L5-m36.4-CD8TM-41BB-CD3ゼータ)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDTKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGGGGGSGGGGSGGGGSGGGGSGGGGSQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSSAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
配列番号65は、LTG1948中に含有される結合した抗HIVバインダ(m36.4-L3-mD1.22)の核酸配列である:
CAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGGAGGTGGCGGTTCAGGCGGAGGGGGGAGTGGAGGTGGGGGAAGCAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGC
配列番号66は、LTG1948中に含有される結合した抗HIVバインダ(m36.4-L3-mD1.22)のアミノ酸配列である:
QVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSSGGGGSGGGGSGGGGSKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVG
配列番号67は、抗HIV CAR LTG1948(LP-m36.4-L3-mD1.22-CD8TM-41BB-CD3ゼータ)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACCCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGGAGGTGGCGGTTCAGGCGGAGGGGGGAGTGGAGGTGGGGGAAGCAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGCGGCCGCAACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGGTAG
配列番号68は、抗HIV CAR LTG1948(LP-m36.4-L3-mD1.22-CD8TM-41BB-CD3ゼータ)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDTQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSSGGGGSGGGGSGGGGSKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
配列番号69は、LTG2303およびLTG2322の中に含有され1つの細胞中に一緒に発現させた抗HIVバインダ(mD1.22およびm36.4)の核酸配列である:
AAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGG-
CAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA
配列番号70は、LTG2303およびLTG2322中に含有され1つの細胞中に一緒に発現させた抗HIVバインダ(mD1.22およびm36.4)のアミノ酸配列である:
KKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVG-
QVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSS
配列番号71は、抗HIV CAR LTG2303(LP-mD1.22-CD8TM-41BB-CD3ゼータ-F2AF-LP2-m36.4-TNFRSF19TM-CD3ゼータ2)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACCAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGGGCGGCCGCAACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGGCGCGCGAAACGCAGCGGCAGCGGCGCGACCAACTTTAGCCTGCTGAAACAGGCGGGCGATGTGGAAGAAAACCCGGGCCCGCGAGCAAAGAGGATGGGAATTCAGGGGGGTTCCGTGCTCTTTGGCTTGCTCCTGGTCCTGGCAGTGTTTTGTCACTCGGGACACAGCCTGCAGCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCACCGGCTCCACGACCACCCACTCCAGCCCCAACGATTGCGAGCCAACCTCTCAGTCTTCGGCCCGAGGCTTGCAGGCCAGCCGCAGGAGGAGCAGTGCACACCCGAGGACTGGATTTCGATACCGCACTGGCGGCCGTGATCTGTAGCGCCCTGGCCACCGTGCTGCTGGCGCTGCTCATCCTTTGCGTGATCTACTGCAAGCGGCAGCGGGTTAAATTCTCCCGCAGCGCAGACGCACCCGCCTACCAGCAAGGACAGAATCAGCTCTACAACGAACTGAACCTTGGTAGGAGAGAAGAATATGATGTTCTCGACAAGCGCAGAGGGAGAGATCCAGAGATGGGTGGGAAGCCGCAACGCCGGAAAAACCCACAAGAGGGACTGTACAATGAATTGCAGAAAGATAAGATGGCCGAGGCTTACTCAGAAATCGGAATGAAGGGGGAGCGGCGGAGGGGCAAGGGACATGATGGTCTCTACCAAGGGCTTTCAACCGCTACTAAGGACACTTATGACGCACTCCACATGCAGGCGCTGCCTCCGCGATAA
配列番号72は、抗HIV CAR LTG2303(LP-mD1.22-CD8TM-41BB-CD3ゼータ-F2AF-LP2-m36.4-TNFRSF19TM-CD3ゼータ2)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDTKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRRAKRSGSGATNFSLLKQAGDVEENPGPRAKRMGIQGGSVLFGLLLVLAVFCHSGHSLQQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSSPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFDTALAAVICSALATVLLALLILCVIYCKRQRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
配列番号73は、抗HIV CAR LTG2322(LP-mD1.22-CD8TM-41BB-CD3ゼータ-F2AF-LP2-m36.4-TNFRSF19TM)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACCAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGGGCGGCCGCAACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGGCGCGCGAAACGCAGCGGCAGCGGCGCGACCAACTTTAGCCTGCTGAAACAGGCGGGCGATGTGGAAGAAAACCCGGGCCCGCGAGCAAAGAGGATGGGAATTCAGGGGGGTTCCGTGCTCTTTGGCTTGCTCCTGGTCCTGGCAGTGTTTTGTCACTCGGGACACAGCCTGCAGCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCACCGGCTCCACGACCACCCACTCCAGCCCCAACGATTGCGAGCCAACCTCTCAGTCTTCGGCCCGAGGCTTGCAGGCCAGCCGCAGGAGGAGCAGTGCACACCCGAGGACTGGATTTCGATACCGCACTGGCGGCCGTGATCTGTAGCGCCCTGGCCACCGTGCTGCTGGCGCTGCTCATCCTTTGCGTGATCTACTGCAAGCGGCAGTAG
配列番号74は、抗HIV CAR LTG2322(LP-mD1.22-CD8TM-41BB-CD3ゼータ-F2AF-LP2-m36.4-TNFRSF19TM)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDTKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRRAKRSGSGATNFSLLKQAGDVEENPGPRAKRMGIQGGSVLFGLLLVLAVFCHSGHSLQQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSSPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFDTALAAVICSALATVLLALLILCVIYCKRQ
配列番号75は、LTG2314中の結合した抗HIVバインダ(mD1.22-L3-C46)の核酸配列である:
AAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGGAGGTGGCGGTTCAGGCGGAGGGGGGAGTGGAGGTGGGGGAAGCTGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTC
配列番号76は、LTG2314中の結合した抗HIVバインダ(mD1.22-L3-C46)のアミノ酸配列である:
KKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGGGGGSGGGGSGGGGSWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF
配列番号77は、抗HIV CAR LTG2314(LP-mD1.22-L3-C46-CD8TM-41BB-CD3ゼータ)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACCAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGGAGGTGGCGGTTCAGGCGGAGGGGGGAGTGGAGGTGGGGGAAGCTGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTCGCGGCCGCAACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGGTAG
配列番号78は、抗HIV CAR LTG2314(LP-mD1.22-L3-C46-CD8TM-41BB-CD3ゼータ)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDTKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGGGGGSGGGGSGGGGSWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
配列番号79は、LTG2315中の結合した抗HIVバインダ(mD1.22-L5-C46)の核酸配列である:
AAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGGCGGAGGCGGGTCAGGTGGCGGTGGTAGTGGCGGTGGCGGTTCAGGCGGTGGTGGGAGTGGGGGAGGAGGCAGCTGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTC
配列番号80は、LTG2315中の結合した抗HIVバインダ(mD1.22-L5-C46)のアミノ酸配列である:
KKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGGGGGSGGGGSGGGGSGGGGSGGGGSWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF
配列番号81は、抗HIV CAR LTG2315(LP-mD1.22-L5-C46-CD8TM-41BB-CD3ゼータ)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACCAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGGCGGAGGCGGGTCAGGTGGCGGTGGTAGTGGCGGTGGCGGTTCAGGCGGTGGTGGGAGTGGGGGAGGAGGCAGCTGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTCGCGGCCGCAACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGGTAG
配列番号82は、抗HIV CAR LTG2315(LP-mD1.22-L5-C46-CD8TM-41BB-CD3ゼータ)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDTKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGGGGGSGGGGSGGGGSGGGGSGGGGSWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
配列番号83は、1つの細胞中に発現させたLTG2316中の結合した抗HIVバインダ(C46-L3-mD1.22)の核酸配列である:
TGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTCGGCGGAGGGGGGAGTGGAGGTGGCGGTTCAGGAGGTGGGGGAAGCAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGC
配列番号84は、LTG2316中の結合した抗HIVバインダ(C46-L3-mD1.22)のアミノ酸配列である:
WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFGGGGSGGGGSGGGGSKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVG
配列番号85は、抗HIV CAR LTG2316(LP-C46-L3-mD1.22-CD8TM-41BB-CD3ゼータ)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACCTGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTCGGCGGAGGGGGGAGTGGAGGTGGCGGTTCAGGAGGTGGGGGAAGCAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGCGGCCGCAACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGGTAG
配列番号86は、抗HIV CAR LTG2316(LP-C46-L3-mD1.22-CD8TM-41BB-CD3ゼータ)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFGGGGSGGGGSGGGGSKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
配列番号87は、1つの細胞中に発現させたLTG2317中の結合した抗HIVバインダ(C46-L5-mD1.22)の核酸配列である:
TGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTCGGCGGAGGGGGGAGTGGAGGTGGCGGTTCAGGAGGTGGGGGAAGCGGTGGCGGTGGTAGTGGCGGTGGCGGTTCAAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGC
配列番号88は、LTG2317(C46-L5-mD1.22)中の結合した抗HIVバインダのアミノ酸配列である:
WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFGGGGSGGGGSGGGGSGGGGSGGGGSKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVG
配列番号89は、抗HIV CAR LTG2317(LP-C46-L5-mD1.22-CD8TM-41BB-CD3ゼータ)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACCTGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTCGGCGGAGGGGGGAGTGGAGGTGGCGGTTCAGGAGGTGGGGGAAGCGGTGGCGGTGGTAGTGGCGGTGGCGGTTCAAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGCGGCCGCAACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGGTAG
配列番号90は、抗HIV CAR LTG2317(LP-C46-L5-mD1.22-CD8TM-41BB-CD3ゼータ)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFGGGGSGGGGSGGGGSGGGGSGGGGSKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
配列番号91は、LTG2318中の結合した抗HIVバインダ(mD1.22-L3-m36.4-L3-C46)の核酸配列である:
AAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGGAGGTGGCGGTTCAGGCGGAGGGGGGAGTGGAGGTGGGGGAAGCCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGGTGGAGGGGGCTCTGGCGGTGGAGGGTCCGGGGGAGGTGGCTCGTGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTC
配列番号92は、LTG2318中の結合した抗HIVバインダ(mD1.22-L3-m36.4-L3-C46)のアミノ酸配列である:
KKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGGGGGSGGGGSGGGGSQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSSGGGGSGGGGSGGGGSWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF
配列番号93は、抗HIV CAR LTG2318(LP-mD1.22-L3-m36.4-L3-C46-CD8TM-41BB-CD3ゼータ)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACCAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGGAGGTGGCGGTTCAGGCGGAGGGGGGAGTGGAGGTGGGGGAAGCCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGGTGGAGGGGGCTCTGGCGGTGGAGGGTCCGGGGGAGGTGGCTCGTGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTCGCGGCCGCAACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGGTAG
配列番号94は、抗HIV CAR LTG2318(LP-mD1.22-L3-m36.4-L3-C46-CD8TM-41BB-CD3ゼータ)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDTKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGGGGGSGGGGSGGGGSQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSSGGGGSGGGGSGGGGSWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
配列番号95は、LTG2319中の結合した抗HIVバインダ(mD1.22-L3-C46-L3-m36.4)の核酸配列である:
AAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGGAGGTGGCGGTTCAGGCGGAGGGGGGAGTGGAGGTGGGGGAAGCTGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTCGGTGGAGGGGGCTCTGGCGGTGGAGGGTCCGGGGGAGGTGGCTCGCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA
配列番号96は、LTG2319中の結合した抗HIVバインダ(mD1.22-L3-C46-L3-m36.4)のアミノ酸配列である
KKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGGGGGSGGGGSGGGGSWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFGGGGSGGGGSGGGGSQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSS
配列番号97は、抗HIV CAR LTG2319(LP-mD1.22-L3-C46-L3-m36.4-CD8TM-41BB-CD3ゼータ)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACCAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGGAGGTGGCGGTTCAGGCGGAGGGGGGAGTGGAGGTGGGGGAAGCTGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTCGGTGGAGGGGGCTCTGGCGGTGGAGGGTCCGGGGGAGGTGGCTCGCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGCGGCCGCAACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGGTAG
配列番号98は、抗HIV CAR LTG2319(LP-mD1.22-L3-C46-L3-m36.4-CD8TM-41BB-CD3ゼータ)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDTKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGGGGGSGGGGSGGGGSWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFGGGGSGGGGSGGGGSQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSSAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
配列番号99は、LTG2320中の結合した抗HIVバインダ(C46-L3-mD1.22-L3-m36.4)の核酸配列である:
TGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTCGGTGGAGGGGGCTCTGGCGGTGGAGGGTCCGGGGGAGGTGGCTCGAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGGAGGTGGCGGTTCAGGCGGAGGGGGGAGTGGAGGTGGGGGAAGCCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA
配列番号100は、LTG2320中の結合した抗HIVバインダ(C46-L3-mD1.22-L3-m36.4)のアミノ酸配列である:
WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFGGGGSGGGGSGGGGSKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGGGGGSGGGGSGGGGSQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSS
配列番号101は、抗HIV CAR LTG2320(LP-C46-L3-mD1.22-L3-m36.4-CD8TM-41BB-CD3ゼータ)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACCTGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTCGGTGGAGGGGGCTCTGGCGGTGGAGGGTCCGGGGGAGGTGGCTCGAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGGAGGTGGCGGTTCAGGCGGAGGGGGGAGTGGAGGTGGGGGAAGCCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGCGGCCGCAACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGGTAG
配列番号102は、抗HIV CAR LTG2320(LP-C46-L3-mD1.22-L3-m36.4-CD8TM-41BB-CD3ゼータ)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFGGGGSGGGGSGGGGSKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGGGGGSGGGGSGGGGSQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSSAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
配列番号103は、同じ細胞中に発現させたLTG2323中に含有される抗HIVバインダ(mD1.22-L3-m36.4およびC46)の核酸配列である:
AAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGGGGAGGTGGCGGTTCAGGCGGAGGGGGGAGTGGAGGTGGGGGAAGCCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA-TGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTC
配列番号104は、同じ細胞中に発現させたLTG2323中に含有される抗HIVバインダ(mD1.22-L3-m36.4およびC46)のアミノ酸配列である:
KKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGGGGGSGGGGSGGGGSQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSS-WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF
配列番号105は、抗HIV CAR LTG2323(LP-mD1.22-L3-m36.4-CD8TM-41BB-CD3ゼータ-F2AF-LP2-C46-TNFRSF19TM)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACCAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGGGGAGGTGGCGGTTCAGGCGGAGGGGGGAGTGGAGGTGGGGGAAGCCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGCGGCCGCAACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGGCGCGCGAAACGCAGCGGCAGCGGCGCGACCAACTTTAGCCTGCTGAAACAGGCGGGCGATGTGGAAGAAAACCCGGGCCCGCGAGCAAAGAGGATGGGAATTCAGGGGGGTTCCGTGCTCTTTGGCTTGCTCCTGGTCCTGGCAGTGTTTTGTCACTCGGGACACAGCCTGCAGTGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTCCCGGCTCCACGACCACCCACTCCAGCCCCAACGATTGCGAGCCAACCTCTCAGTCTTCGGCCCGAGGCTTGCAGGCCAGCCGCAGGAGGAGCAGTGCACACCCGAGGACTGGATTTCGATACCGCACTGGCGGCCGTGATCTGTAGCGCCCTGGCCACCGTGCTGCTGGCGCTGCTCATCCTTTGCGTGATCTACTGCAAGCGGCAGTAG
配列番号106は、抗HIV CAR LTG2323(LP-mD1.22-L3-m36.4-CD8TM-41BB-CD3ゼータ-F2AF-LP2-C46-TNFRSF19TM)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDTKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGGGGGSGGGGSGGGGSQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSSAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRRAKRSGSGATNFSLLKQAGDVEENPGPRAKRMGIQGGSVLFGLLLVLAVFCHSGHSLQWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFDTALAAVICSALATVLLALLILCVIYCKRQ
配列番号107は、抗HIV CAR LTG2329(LP-C46-L3-mD1.22-CD8TM-41BB-CD3ゼータ-F2AF-LP2-m36.4-TNFRSF19TM-CD3ゼータ2)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACCTGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTCGGCGGAGGGGGGAGTGGAGGTGGCGGTTCAGGAGGTGGGGGAAGCAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGCGGCCGCAACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGGCGCGCGAAACGCAGCGGCAGCGGCGCGACCAACTTTAGCCTGCTGAAACAGGCGGGCGATGTGGAAGAAAACCCGGGCCCGCGAGCAAAGAGGATGGGAATTCAGGGGGGTTCCGTGCTCTTTGGCTTGCTCCTGGTCCTGGCAGTGTTTTGTCACTCGGGACACAGCCTGCAGCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCACCGGCTCCACGACCACCCACTCCAGCCCCAACGATTGCGAGCCAACCTCTCAGTCTTCGGCCCGAGGCTTGCAGGCCAGCCGCAGGAGGAGCAGTGCACACCCGAGGACTGGATTTCGATACCGCACTGGCGGCCGTGATCTGTAGCGCCCTGGCCACCGTGCTGCTGGCGCTGCTCATCCTTTGCGTGATCTACTGCAAGCGGCAGCGGGTTAAATTCTCCCGCAGCGCAGACGCACCCGCCTACCAGCAAGGACAGAATCAGCTCTACAACGAACTGAACCTTGGTAGGAGAGAAGAATATGATGTTCTCGACAAGCGCAGAGGGAGAGATCCAGAGATGGGTGGGAAGCCGCAACGCCGGAAAAACCCACAAGAGGGACTGTACAATGAATTGCAGAAAGATAAGATGGCCGAGGCTTACTCAGAAATCGGAATGAAGGGGGAGCGGCGGAGGGGCAAGGGACATGATGGTCTCTACCAAGGGCTTTCAACCGCTACTAAGGACACTTATGACGCACTCCACATGCAGGCGCTGCCTCCGCGATAA
配列番号108は、抗HIV CAR LTG2329(LP-C46-L3-mD1.22-CD8TM-41BB-CD3ゼータ-F2AF-LP2-m36.4-TNFRSF19TM-CD3ゼータ2)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFGGGGSGGGGSGGGGSKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRRAKRSGSGATNFSLLKQAGDVEENPGPRAKRMGIQGGSVLFGLLLVLAVFCHSGHSLQQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSSPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFDTALAAVICSALATVLLALLILCVIYCKRQRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
配列番号109は、抗HIV CAR LTG2330(LP-C46-L5-mD1.22-CD8TM-41BB-CD3ゼータ-F2AF-LP2-m36.4TNFRSF19TM-CD3ゼータ2)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACCTGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTCGGCGGAGGGGGGAGTGGAGGTGGCGGTTCAGGAGGTGGGGGAAGCGGTGGCGGTGGTAGTGGCGGTGGCGGTTCAAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGCGGCCGCAACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGGCGCGCGAAACGCAGCGGCAGCGGCGCGACCAACTTTAGCCTGCTGAAACAGGCGGGCGATGTGGAAGAAAACCCGGGCCCGCGAGCAAAGAGGATGGGAATTCAGGGGGGTTCCGTGCTCTTTGGCTTGCTCCTGGTCCTGGCAGTGTTTTGTCACTCGGGACACAGCCTGCAGCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCACCGGCTCCACGACCACCCACTCCAGCCCCAACGATTGCGAGCCAACCTCTCAGTCTTCGGCCCGAGGCTTGCAGGCCAGCCGCAGGAGGAGCAGTGCACACCCGAGGACTGGATTTCGATACCGCACTGGCGGCCGTGATCTGTAGCGCCCTGGCCACCGTGCTGCTGGCGCTGCTCATCCTTTGCGTGATCTACTGCAAGCGGCAGCGGGTTAAATTCTCCCGCAGCGCAGACGCACCCGCCTACCAGCAAGGACAGAATCAGCTCTACAACGAACTGAACCTTGGTAGGAGAGAAGAATATGATGTTCTCGACAAGCGCAGAGGGAGAGATCCAGAGATGGGTGGGAAGCCGCAACGCCGGAAAAACCCACAAGAGGGACTGTACAATGAATTGCAGAAAGATAAGATGGCCGAGGCTTACTCAGAAATCGGAATGAAGGGGGAGCGGCGGAGGGGCAAGGGACATGATGGTCTCTACCAAGGGCTTTCAACCGCTACTAAGGACACTTATGACGCACTCCACATGCAGGCGCTGCCTCCGCGATAA
配列番号110は、抗HIV CAR LTG2330(LP-C46-L5-mD1.22-CD8TM-41BB-CD3ゼータ-F2AF-LP2-m36.4-TNFRSF19TM-CD3ゼータ2)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFGGGGSGGGGSGGGGSGGGGSGGGGSKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRRAKRSGSGATNFSLLKQAGDVEENPGPRAKRMGIQGGSVLFGLLLVLAVFCHSGHSLQQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSSPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFDTALAAVICSALATVLLALLILCVIYCKRQRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
配列番号111は、同じ細胞中に発現させたLTG2329およびLTG2331中に含有される抗HIVバインダ(C46-L3-mD1.22およびm36.4)の核酸配列である:
TGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTCGGCGGAGGGGGGAGTGGAGGTGGCGGTTCAGGAGGTGGGGGAAGCAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGC-
CAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA
配列番号112は、同じ細胞中に発現させたLTG2329およびLTG2331中に含有される抗HIVバインダ(C46-L3-mD1.22およびm36.4)のアミノ酸配列である:
WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFGGGGSGGGGSGGGGSKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVG-
QVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSS
配列番号113は、抗HIV CAR LTG2331(LP-C46-L3-mD1.22-CD8TM-41BB-CD3ゼータ-F2AF-LP2-m36.4-TNFRSF19TM)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACCTGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTCGGCGGAGGGGGGAGTGGAGGTGGCGGTTCAGGAGGTGGGGGAAGCAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGCGGCCGCAACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGGCGCGCGAAACGCAGCGGCAGCGGCGCGACCAACTTTAGCCTGCTGAAACAGGCGGGCGATGTGGAAGAAAACCCGGGCCCGCGAGCAAAGAGGATGGGAATTCAGGGGGGTTCCGTGCTCTTTGGCTTGCTCCTGGTCCTGGCAGTGTTTTGTCACTCGGGACACAGCCTGCAGCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCACCGGCTCCACGACCACCCACTCCAGCCCCAACGATTGCGAGCCAACCTCTCAGTCTTCGGCCCGAGGCTTGCAGGCCAGCCGCAGGAGGAGCAGTGCACACCCGAGGACTGGATTTCGATACCGCACTGGCGGCCGTGATCTGTAGCGCCCTGGCCACCGTGCTGCTGGCGCTGCTCATCCTTTGCGTGATCTACTGCAAGCGGCAGTAG
配列番号114は、抗HIV CAR LTG2331(LP-C46-L3-mD1.22-CD8TM-41BB-CD3ゼータ-F2AF-LP2-m36.4-TNFRSF19TM)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFGGGGSGGGGSGGGGSKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRRAKRSGSGATNFSLLKQAGDVEENPGPRAKRMGIQGGSVLFGLLLVLAVFCHSGHSLQQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSSPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFDTALAAVICSALATVLLALLILCVIYCKRQ
配列番号115は、同じ細胞中に発現させたLTG2330およびLTG2332中に含有される抗HIVバインダ(C46-L5-mD1.22およびm36.4)の核酸配列である:
TGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTCGGCGGAGGGGGGAGTGGAGGTGGCGGTTCAGGAGGTGGGGGAAGCGGTGGCGGTGGTAGTGGCGGTGGCGGTTCAAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGC-
CAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA
配列番号116は、同じ細胞中に発現させたLTG2330およびLTG2332中に含有される抗HIVバインダ(C46-L5-mD1.22およびm36.4)のアミノ酸配列である:
WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFGGGGSGGGGSGGGGSGGGGSGGGGSKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVG-
QVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSS
配列番号117は、抗HIV CAR LTG2332(LP-C46-L5-mD1.22-CD8TM-41BB-CD3ゼータ-F2AF-LP2-m36.4-TNFRSF19TM)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACCTGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTCGGCGGAGGGGGGAGTGGAGGTGGCGGTTCAGGAGGTGGGGGAAGCGGTGGCGGTGGTAGTGGCGGTGGCGGTTCAAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGCGGCCGCAACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGGCGCGCGAAACGCAGCGGCAGCGGCGCGACCAACTTTAGCCTGCTGAAACAGGCGGGCGATGTGGAAGAAAACCCGGGCCCGCGAGCAAAGAGGATGGGAATTCAGGGGGGTTCCGTGCTCTTTGGCTTGCTCCTGGTCCTGGCAGTGTTTTGTCACTCGGGACACAGCCTGCAGCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCACCGGCTCCACGACCACCCACTCCAGCCCCAACGATTGCGAGCCAACCTCTCAGTCTTCGGCCCGAGGCTTGCAGGCCAGCCGCAGGAGGAGCAGTGCACACCCGAGGACTGGATTTCGATACCGCACTGGCGGCCGTGATCTGTAGCGCCCTGGCCACCGTGCTGCTGGCGCTGCTCATCCTTTGCGTGATCTACTGCAAGCGGCAGTAG
配列番号118は、抗HIV CAR LTG2332(LP-C46-L5-mD1.22-CD8TM-41BB-CD3ゼータ-F2AF-LP2-m36.4-TNFRSF19TM)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFGGGGSGGGGSGGGGSGGGGSGGGGSKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRRAKRSGSGATNFSLLKQAGDVEENPGPRAKRMGIQGGSVLFGLLLVLAVFCHSGHSLQQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSSPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFDTALAAVICSALATVLLALLILCVIYCKRQ
配列番号119は、同じ細胞中に発現させたLTG2334中に含有される抗HIVバインダ(mD1.22-L5-m36.4およびC46)の核酸配列である:
AAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGGCGGAGGCGGGTCAGGTGGCGGTGGTAGTGGCGGTGGCGGTTCAGGCGGTGGTGGGAGTGGGGGAGGAGGCAGCCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA-
TGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTC
配列番号120は、同じ細胞中に発現させたLTG2334中に含有される抗HIVバインダ(mD1.22-L5-m36.4およびC46)のアミノ酸配列である:
KKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGGGGGSGGGGSGGGGSGGGGSGGGGSQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSS-
WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF
配列番号121は、抗HIV CAR LTG2334(LP-mD1.22-L5-m36.4-CD8TM-41BB-CD3ゼータ-F2AF-LP2-C46-TNFRSF19TM)の核酸配列である:
ATGCTTCTCCTGGTCACCTCCCTGCTCCTCTGCGAACTGCCTCACCCTGCCTTCCTTCTGATTCCTGACACCAAGAAAGTCGTGTACGGAAAGAAGGGAGACACTGTGGAGCTGACCTGTACCGCAAGCCAGAAGAAGAACATCCAGTTCCACTGGAAGAACTCCAACCAAATCAAGATCCTGGGGAACCAGGGTTCCTTCCTGACTAAGGGACCCTCAAAGCTGAACGACCGCGTGGATAGCAGACGCTCCCTGTGGGACCAGGGAAACTTCCCGCTTATCATTAAGAACCTCAAACCTGAGGACTCGGATACCTACATCTGCGAAGTGGAGGACCAGAAGGAGGAGGTGCAGCTGGTGGTGGTGGGCGGCGGAGGCGGGTCAGGTGGCGGTGGTAGTGGCGGTGGCGGTTCAGGCGGTGGTGGGAGTGGGGGAGGAGGCAGCCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGCTTTCGATTTCTCTGATTATGAAATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATGATAGTGGAAACACCATTTACAATCCGTCCCTCAAGAGTCGAGTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACACCCTGAGAGCCGAGGACACAGCCATATATTACTGTGCGATATATGGTGGTAACTCCGGGGGAGAGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGCGGCCGCAACTACCACCCCTGCCCCTCGGCCGCCGACTCCGGCCCCAACCATCGCAAGCCAACCCCTCTCCTTGCGCCCCGAAGCTTGCCGCCCGGCCGCGGGTGGAGCCGTGCATACCCGGGGGCTGGACTTTGCCTGCGATATCTACATTTGGGCCCCGCTGGCCGGCACTTGCGGCGTGCTCCTGCTGTCGCTGGTCATCACCCTTTACTGCAAGAGGGGCCGGAAGAAGCTGCTTTACATCTTCAAGCAGCCGTTCATGCGGCCCGTGCAGACGACTCAGGAAGAGGACGGATGCTCGTGCAGATTCCCTGAGGAGGAAGAGGGGGGATGCGAACTGCGCGTCAAGTTCTCACGGTCCGCCGACGCCCCCGCATATCAACAGGGCCAGAATCAGCTCTACAACGAGCTGAACCTGGGAAGGAGAGAGGAGTACGACGTGCTGGACAAGCGACGCGGACGCGACCCGGAGATGGGGGGGAAACCACGGCGGAAAAACCCTCAGGAAGGACTGTACAACGAACTCCAGAAAGACAAGATGGCGGAAGCCTACTCAGAAATCGGGATGAAGGGAGAGCGGAGGAGGGGAAAGGGTCACGACGGGCTGTACCAGGGACTGAGCACCGCCACTAAGGATACCTACGATGCCTTGCATATGCAAGCACTCCCACCCCGGCGCGCGAAACGCAGCGGCAGCGGCGCGACCAACTTTAGCCTGCTGAAACAGGCGGGCGATGTGGAAGAAAACCCGGGCCCGCGAGCAAAGAGGATGGGAATTCAGGGGGGTTCCGTGCTCTTTGGCTTGCTCCTGGTCCTGGCAGTGTTTTGTCACTCGGGACACAGCCTGCAGTGGATGGAATGGGATCGCGAAATCAACAACTACACCTCCCTGATTCACTCCCTGATTGAGGAATCCCAGAATCAACAGGAGAAGAACGAACAAGAGCTTCTGGAGCTGGACAAATGGGCCTCCCTGTGGAACTGGTTCCCGGCTCCACGACCACCCACTCCAGCCCCAACGATTGCGAGCCAACCTCTCAGTCTTCGGCCCGAGGCTTGCAGGCCAGCCGCAGGAGGAGCAGTGCACACCCGAGGACTGGATTTCGATACCGCACTGGCGGCCGTGATCTGTAGCGCCCTGGCCACCGTGCTGCTGGCGCTGCTCATCCTTTGCGTGATCTACTGCAAGCGGCAGTAG
配列番号122は、抗HIV CAR LTG2334(LP-mD1.22-L5-m36.4-CD8TM-41BB-CD3ゼータ-F2AF-LP2-C46-TNFRSF19TM)のアミノ酸配列である:
MLLLVTSLLLCELPHPAFLLIPDTKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGGGGGSGGGGSGGGGSGGGGSGGGGSQVQLVQSGGGLVQPGGSLRLSCAASAFDFSDYEMSWVREAPGKGLEWIGEINDSGNTIYNPSLKSRVTISRDNSKNTLYLQMNTLRAEDTAIYYCAIYGGNSGGEYWGQGTLVTVSSAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRRAKRSGSGATNFSLLKQAGDVEENPGPRAKRMGIQGGSVLFGLLLVLAVFCHSGHSLQWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFDTALAAVICSALATVLLALLILCVIYCKRQ
Claims (18)
- 少なくとも1つの細胞外の抗HIV抗原結合ドメインを含むキメラ抗原受容体(CAR)をコードする単離された核酸分子であって、配列番号69を含む核酸配列でコードされる、mD1.22とm36.4を直接つないだ細胞外の抗HIVエンベロープ抗原結合ドメイン、または、配列番号115を含む核酸配列でコードされる、(GGGGS) 5 リンカー配列を介してC46とmD1.22をつなぎ、mD1.22とm36.4を直接つないだ細胞外の抗HIVエンベロープ抗原結合ドメインを含む少なくとも1つの細胞外の抗原結合ドメインと、少なくとも1つの膜貫通ドメインと、少なくとも1つの細胞内シグナル伝達ドメインとをコードする、単離された核酸分子。
- 請求項1に記載の核酸分子を含むベクター。
- 前記ベクターは、DNAベクター、RNAベクター、プラスミドベクター、コスミドベクター、ヘルペスウイルスベクター、麻疹ウイルスベクター、レンチウイルスベクター、アデノウイルスベクター、およびレトロウイルスベクター、またはこれらの組み合わせからなる群より選択される、請求項2に記載のベクター。
- 請求項2に記載のベクターを含む細胞。
- 請求項2に記載のベクターをT細胞に形質導入する工程を含む、細胞作製方法。
- 抗HIV有効量のヒトのT細胞の集団を含む医薬組成物であって、ヒトのT細胞の集団は、キメラ抗原受容体(CAR)をコードする核酸配列を含み、前記CARは、配列番号70のアミノ酸配列を含む、mD1.22とm36.4を直接つないだ細胞外の抗HIV抗原結合ドメイン、または、配列番号116のアミノ酸配列を含む、(GGGGS) 5 リンカー配列を介してC46とmD1.22をつなぎ、mD1.22とm36.4を直接つないだ細胞外の抗HIV抗原結合ドメインを含む少なくとも1つの細胞外の抗原結合ドメインと、少なくとも1つのリンカードメインと、少なくとも1つの膜貫通ドメインと、少なくとも1つの細胞内シグナル伝達ドメインとを含み、ここにおいてT細胞の集団は、HIV/AIDSを有するヒト対象のT細胞である、医薬組成物。
- それを必要とする対象におけるHIVに関連するがんまたはHIV/AIDSを処置する医薬組成物を製造するためのT細胞の集団の使用であって、ここにおいてT細胞の集団はキメラ抗原受容体(CAR)をコードする核酸配列を含み、
前記CARは、少なくとも1つの細胞外の抗HIV抗原結合ドメイン、少なくとも1つのリンカーまたはスペーサドメイン、少なくとも1つの膜貫通ドメイン、少なくとも1つの細胞内シグナル伝達ドメインを含み、ここにおいてmD1.22とm36.4を直接つないだ細胞外の抗HIV抗原結合ドメインをコードする核酸配列は配列番号69を含む核酸配列を含み、ここにおいてT細胞の集団は、HIV/AIDSを有する対象のT細胞である、使用。 - 少なくとも1つの膜貫通ドメインは、T細胞受容体のアルファ、ベータ、もしくはゼータ鎖、CD8、CD28、CD3イプシロン、CD45、CD4、CD5、CD9、CD16、CD22、CD33、CD37、CD64、CD80、CD86、CD134、CD137、およびCD154からなる群から選択されたタンパク質の膜貫通ドメインを含む、請求項7に記載の使用。
- 対象がHIVに関連するがんを有する、請求項7に記載の使用。
- 少なくとも1つの細胞外の抗HIVエンベロープ抗原結合ドメインは、HIV-1エンベロープタンパク質に結合する、請求項7に記載の使用。
- 少なくとも1つの細胞外の抗HIV抗原結合ドメイン、少なくとも1つの細胞内シグナル伝達ドメイン、またはその両方は、リンカーまたはスペーサドメインによって、少なくとも1つの膜貫通ドメインに結合される、請求項7に記載の使用。
- 少なくとも1つのリンカーまたはスペーサドメインは、CD8の細胞外ドメインに由来し、かつ、少なくとも1つの膜貫通ドメインに結合している、請求項11に記載の使用。
- 少なくとも1つの細胞内シグナル伝達ドメインは、CD3ゼータ細胞内ドメインをさらに含む、請求項7に記載の使用。
- 少なくとも1つの細胞内シグナル伝達ドメインは、共刺激ドメイン、一次シグナル伝達ドメインまたはそれらの組み合わせを含む、請求項7に記載の使用。
- 少なくとも1つの細胞内シグナル伝達ドメインは、OX40、CD70、CD27、CD28、CD5、ICAM-1、LFA-1(CD11a/CD18)、ICOS(CD278)、DAP10、DAP12、および4-1BB(CD137)からなる群から選択されたタンパク質の機能的シグナル伝達ドメインを含む共刺激ドメインを含む、請求項7に記載の使用。
- それを必要とする対象におけるHIVに関連するがんまたはHIV/AIDSを処置する医薬組成物を製造するためのT細胞の集団の使用であって、ここにおいてT細胞の集団はキメラ抗原受容体(CAR)をコードする核酸配列を含み、
前記CARは、少なくとも1つの細胞外の抗HIV抗原結合ドメイン、少なくとも1つのリンカーまたはスペーサドメイン、少なくとも1つの膜貫通ドメイン、少なくとも1つの細胞内シグナル伝達ドメインを含み、ここにおいて(GGGGS) 5 リンカー配列を介してC46とmD1.22をつなぎ、mD1.22とm36.4を直接つないだ細胞外の抗HIV抗原結合ドメインをコードする核酸配列は配列番号115を含む核酸配列を含み、ここにおいてT細胞の集団は、HIV/AIDSを有する対象のT細胞である、使用。 - それを必要とする対象におけるHIVに関連するがんまたはHIV/AIDSを処置する医薬組成物を製造するためのT細胞の集団の使用であって、ここにおいてT細胞の集団はキメラ抗原受容体(CAR)をコードする核酸配列を含み、
前記CARは、少なくとも1つの細胞外の抗HIV抗原結合ドメイン、少なくとも1つのリンカーまたはスペーサドメイン、少なくとも1つの膜貫通ドメイン、少なくとも1つの細胞内シグナル伝達ドメインを含み、ここにおいて少なくとも1つの細胞外の抗HIV抗原結合ドメインは配列番号70のアミノ酸配列を含み、mD1.22とm36.4を直接つないだものであり、ここにおいてT細胞の集団は、HIV/AIDSを有する対象のT細胞である、使用。 - それを必要とする対象におけるHIVに関連するがんまたはHIV/AIDSを処置する医薬組成物を製造するためのT細胞の集団の使用であって、ここにおいてT細胞の集団はキメラ抗原受容体(CAR)をコードする核酸配列を含み、
前記CARは、少なくとも1つの細胞外の抗HIV抗原結合ドメイン、少なくとも1つのリンカーまたはスペーサドメイン、少なくとも1つの膜貫通ドメイン、少なくとも1つの細胞内シグナル伝達ドメインを含み、ここにおいて少なくとも1つの細胞外の抗HIV抗原結合ドメインは配列番号116のアミノ酸配列を含み、(GGGGS) 5 リンカー配列を介してC46とmD1.22をつなぎ、mD1.22とm36.4を直接つないだものであり、ここにおいてT細胞の集団は、HIV/AIDSを有する対象のT細胞である、使用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023185402A JP2024016109A (ja) | 2017-12-20 | 2023-10-30 | 免疫療法を用いてhiv/aidsを処置するための組成物および方法 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762608479P | 2017-12-20 | 2017-12-20 | |
US62/608,479 | 2017-12-20 | ||
US201862660819P | 2018-04-20 | 2018-04-20 | |
US62/660,819 | 2018-04-20 | ||
PCT/US2018/066744 WO2019126464A2 (en) | 2017-12-20 | 2018-12-20 | Compositions and methods for treating hiv/aids with immunotherapy |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023185402A Division JP2024016109A (ja) | 2017-12-20 | 2023-10-30 | 免疫療法を用いてhiv/aidsを処置するための組成物および方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021506306A JP2021506306A (ja) | 2021-02-22 |
JP7377802B2 true JP7377802B2 (ja) | 2023-11-10 |
Family
ID=66993881
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020534253A Active JP7377802B2 (ja) | 2017-12-20 | 2018-12-20 | 免疫療法を用いてhiv/aidsを処置するための組成物および方法 |
JP2023185402A Pending JP2024016109A (ja) | 2017-12-20 | 2023-10-30 | 免疫療法を用いてhiv/aidsを処置するための組成物および方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023185402A Pending JP2024016109A (ja) | 2017-12-20 | 2023-10-30 | 免疫療法を用いてhiv/aidsを処置するための組成物および方法 |
Country Status (7)
Country | Link |
---|---|
US (2) | US10894819B2 (ja) |
EP (1) | EP3728307A4 (ja) |
JP (2) | JP7377802B2 (ja) |
CN (1) | CN111954677A (ja) |
AU (1) | AU2018388997A1 (ja) |
CA (1) | CA3086612A1 (ja) |
WO (1) | WO2019126464A2 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019126464A2 (en) * | 2017-12-20 | 2019-06-27 | Lentigen Technology, Inc. | Compositions and methods for treating hiv/aids with immunotherapy |
EP3807317A4 (en) * | 2018-06-15 | 2022-03-30 | The Regents of University of California | CHIMERIC FUSION FRAGMENT ANTIGEN RECEPTORS AND USES THEREOF |
AU2021317073A1 (en) * | 2020-07-29 | 2023-02-16 | National Research Council Of Canada | Anti-CD22 single domain antibodies and therapeutic constructs |
CN112341538A (zh) * | 2020-10-27 | 2021-02-09 | 苏州复融生物技术有限公司 | 一种Fc单体多肽及其应用 |
CN114539421B (zh) * | 2020-11-18 | 2024-03-12 | 复旦大学 | 以HIV-1 gp120与CD20为双靶点的CAR-T细胞制备方法及其应用 |
EP4141028A1 (en) * | 2021-08-31 | 2023-03-01 | Johann-Wolfgang-Goethe-Universität Frankfurt am Main | Personalized vnar-based chimeric antigen receptors (vnar-car) for the treatment of clonal b-and t cell malignancies, and methods for producing vnar-cars |
CN114163534B (zh) * | 2021-11-08 | 2023-07-18 | 复旦大学 | 一种靶向hiv-1病毒囊膜蛋白的双特异性嵌合抗原受体及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015017755A1 (en) | 2013-08-02 | 2015-02-05 | The Regents Of The University Of California | Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors |
WO2015077789A2 (en) | 2013-11-25 | 2015-05-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors to control hiv infection |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3060165A (en) | 1962-10-23 | Preparation of toxic ricin | ||
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US5079163A (en) | 1985-03-29 | 1992-01-07 | Cetus Corporation | Recombinant ricin toxin fragments |
US4689401A (en) | 1986-03-06 | 1987-08-25 | Cetus Corporation | Method of recovering microbially produced recombinant ricin toxin a chain |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
US5792458A (en) | 1987-10-05 | 1998-08-11 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant diphtheria toxin conjugates |
US5208021A (en) | 1987-10-05 | 1993-05-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of preparing diphtheria immunotoxins |
IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Noble hydrazonic history of anthracycline and methods for their preparation |
US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗hiv剤 |
US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
JPH07507768A (ja) | 1992-03-12 | 1995-08-31 | アルカーメス コントロールド セラピューティクス,インコーポレイテッド | Acth含有マイクロスフェアの制御放出 |
US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
ES2195036T3 (es) | 1995-12-22 | 2003-12-01 | Bristol Myers Squibb Co | Conectores de hidrazona ramificados. |
EP0973540B1 (en) | 1997-02-25 | 2005-11-02 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18 |
WO2000040616A1 (en) * | 1999-01-08 | 2000-07-13 | Panacos Pharmaceuticals, Inc. | METHODS OF ELICITING BROADLY NEUTRALIZING ANTIBODIES TARGETING HIV-1 gp41 |
US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
US20020197266A1 (en) | 2000-02-08 | 2002-12-26 | Waldemar Debinski | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
ES2556641T3 (es) | 2002-07-31 | 2016-01-19 | Seattle Genetics, Inc. | Conjugados de fármacos y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa |
BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
JP2013505944A (ja) | 2009-09-24 | 2013-02-21 | シアトル ジェネティックス, インコーポレイテッド | Dr5リガンド薬物結合体 |
US20110212088A1 (en) | 2010-02-26 | 2011-09-01 | Sabbadini Roger A | Anti-paf antibodies |
EP2571898B1 (en) * | 2010-05-21 | 2021-07-21 | The United States of America, as represented by The Secretary, Department of Health and Human Services | High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins |
WO2013128027A1 (en) * | 2012-03-01 | 2013-09-06 | Amgen Research (Munich) Gmbh | Long life polypeptide binding molecules |
EP2968453B1 (en) | 2013-03-15 | 2019-12-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Stabilized single human cd4 domains and fusion proteins |
EP3274368A1 (en) * | 2015-03-25 | 2018-01-31 | THE UNITED STATES OF AMERICA, represented by the S | Bispecific multivalent fusion proteins |
EP3307877B1 (en) * | 2015-06-12 | 2020-11-18 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
CA3096798A1 (en) * | 2017-01-09 | 2018-07-12 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-mesothelin immunotherapy |
WO2019126464A2 (en) * | 2017-12-20 | 2019-06-27 | Lentigen Technology, Inc. | Compositions and methods for treating hiv/aids with immunotherapy |
-
2018
- 2018-12-20 WO PCT/US2018/066744 patent/WO2019126464A2/en unknown
- 2018-12-20 US US16/228,077 patent/US10894819B2/en active Active
- 2018-12-20 JP JP2020534253A patent/JP7377802B2/ja active Active
- 2018-12-20 CN CN201880089736.7A patent/CN111954677A/zh active Pending
- 2018-12-20 AU AU2018388997A patent/AU2018388997A1/en active Pending
- 2018-12-20 EP EP18890907.1A patent/EP3728307A4/en active Pending
- 2018-12-20 CA CA3086612A patent/CA3086612A1/en active Pending
-
2020
- 2020-12-15 US US17/122,847 patent/US20210206839A1/en active Pending
-
2023
- 2023-10-30 JP JP2023185402A patent/JP2024016109A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015017755A1 (en) | 2013-08-02 | 2015-02-05 | The Regents Of The University Of California | Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors |
WO2015077789A2 (en) | 2013-11-25 | 2015-05-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors to control hiv infection |
Non-Patent Citations (1)
Title |
---|
Weizao Chen et al.,Exceptionally Potent and Broadly Cross-Reactive, Bispecific Multivalent HIV-1 Inhibitors Based on Single Human CD4 and Antibody Domains.,J. Virol.,2013年11月06日,Vol.88, No.2,p.1125-1139,doi: 10.1128/JVI.02566-13 |
Also Published As
Publication number | Publication date |
---|---|
US20190202895A1 (en) | 2019-07-04 |
AU2018388997A1 (en) | 2020-07-09 |
JP2021506306A (ja) | 2021-02-22 |
US20210206839A1 (en) | 2021-07-08 |
CA3086612A1 (en) | 2019-06-27 |
WO2019126464A3 (en) | 2019-08-08 |
WO2019126464A2 (en) | 2019-06-27 |
EP3728307A4 (en) | 2021-05-19 |
JP2024016109A (ja) | 2024-02-06 |
EP3728307A2 (en) | 2020-10-28 |
CN111954677A (zh) | 2020-11-17 |
US10894819B2 (en) | 2021-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7377802B2 (ja) | 免疫療法を用いてhiv/aidsを処置するための組成物および方法 | |
JP7423610B2 (ja) | DuoCARでがんを処置するための組成物および方法 | |
JP7237926B2 (ja) | 抗cd19/cd20免疫療法によりがんを処置するための組成物および方法 | |
AU2021201484A1 (en) | Chimeric antigen receptors and methods of use | |
US20210353675A1 (en) | Compositions and Methods for Treating Cancer with Anti-CD38 Immunotherapy | |
CN111629735A (zh) | 用于用抗cd22免疫治疗来治疗癌症的组合物和方法 | |
JP2022535005A (ja) | 抗bcma免疫療法によりがんを処置するための組成物および方法 | |
CN116801898A (zh) | 用于用抗cd19/cd22免疫治疗来治疗癌症的组合物和方法 | |
CN113382745B (zh) | 用DuoCAR治疗癌症的组合物和方法 | |
US20240091360A1 (en) | Chimeric Antigen Receptor Therapies for Treating Solid Tumors | |
JP2024054133A (ja) | DuoCARでがんを処置するための組成物および方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211217 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211217 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230303 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230530 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230823 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230829 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230905 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231004 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231030 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7377802 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |